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1 Introduction 
 
Hepatitis C virus (HCV) infects approximately 170 million people worldwide (World Health 
Organization, 1999). The virus was discovered after specific diagnostic tests for both hepatitis 
A virus (HAV) and hepatitis B virus (HBV) which revealed that most cases of post-
transfusion hepatitis were not linked to HAV or HBV (Bradley, 1999). However, it took more 
than 10 years to isolate the agent responsible for this so-called post-transfusion non-A, non-B 
hepatitis (NANBH). In 1989 a new ribonucleic acid (RNA) virus termed HCV was isolated 
with the aid of modern techniques of molecular cloning and phage display (Choo et al., 1989). 
HCV causes a persistent infection in the majority of infected people and can lead to cirrhosis 
of the liver and hepatocellular carcinoma (HCC) (Shimotohno, 2000). For this reason, and the 
high prevalence of infection worldwide, HCV is considered a major human pathogen. 
 
 
1.1 Clinical aspects of HCV infection 
 
The course of disease varies widely among infected persons. HCV infection is hardly ever 
diagnosed during the acute phase. The majority of persons have either none or only mild and 
unspecific symptoms after exposure to HCV. Nevertheless, clinical manifestations of acute 
hepatitis consisting of jaundice, malaise, and nausea can occur in some patients, usually 
within 7 to 8 weeks after infection (Lauer and Walker, 2001). Progression to chronic disease 
occurs in about 50-80% of infected persons, whereas 20-50% show spontaneous recovery 
(Fig. 1.1). The early stage of chronic infection is typically characterized by a prolonged 
asymptomatic period. Once chronic infection has been established, spontaneous clearance of 
viremia is rare. Most chronic infections will lead to hepatitis and to some degree of fibrosis. 
10-20% of those infected chronically develop liver cirrhosis. At this stage of the disease, the 
risk of developing HCC is 1-4% per year (Tsukuma et al., 1993). Factors that increase the risk 
of clinical disease progression include alcohol intake, co-infection with HBV (Zarski et al., 
1998) or human immunodeficiency virus type 1 (HIV-1) (Sanchez-Quijano et al., 1995), male 
sex and older age at infection (Fig. 1.2). In this high-risk group, cirrhosis can develop within 
20 years or less after infection. In contrary, low risk patients often do not have progressive 
liver disease until 30 or more years after infection. In HCV-infected patients, a superinfection 
with HAV can lead to fulminant hepatitis (Vento et al., 1998). 
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In addition to hepatic disease, HCV infection is associated with important extrahepatic 
manifestations. A number of B cell-mediated disorders are associated with HCV infection. 
For example, HCV is the major cause of essential mixed cryoglobulinemia. Cryoglobulins can 
be found in about 50% of HCV patients and 10-15% of infected individuals develop a 
symptomatic disease consisting of weakness, arthralgia and purpura (Horcajada et al., 1999). 
Since cryoglobulins accumulate in kidney, membranoproliferative glomerulonephritis can 
occur as a serious complication (Segerer et al., 2002). A higher incidence of B cell non-
Hodgkin's lymphoma (Pozzato et al., 1994), Sjögren’s syndrome (Haddad et al., 1992), 
autoimmune thyroiditis, idiopathic pulmonary fibrosis and dermatologic manifestations like 
Lichen planus and Porphyria cutanea tarda in association with HCV infection has been 
observed (Zignego and Brechot, 1999).  
 
 
 
 
 
 
 
Fig. 1.1: Disease progression 
 
 
1.2 Treatment 
 
There is currently no vaccine for HCV but treatment is available for patients with chronic 
infection. Both viral [genotype (GT), quasispecies diversity, viral load] and host (gender, age, 
fibrosis etc.) factors (Fig. 1.2), influence the outcome of treatment (Feld and Hoofnagle, 
2005). The current recommended treatment for HCV is a combination therapy of pegylated 
interferon alpha (peg-IFN-α) and ribavirin (Reichard, 1998). Two peg-IFNs are approved for 
treatment, peg-IFN-α-2a (Pegasys; Roche) and peg-IFN-α-2b (peg-Intron; Schering-Plough). 
The current recommendations are therapy with peg-IFN-α and ribavirin for 48 weeks in 
patients infected with GT1 and a shorter 24-week treatment for patients infected with GT2 
and 3. In clinical trials, sustained virological response (SVR) can be achieved in 70-80% of 
non-GT1 patients whereas only 45% of GT1 patients have a SVR (Fig. 1.2). SVR is defined 
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as persistent absence of serum HCV RNA for at least 6 months after cessation of therapy. 
Treatment is recommended for patients with chronic HCV infection with detectable HCV 
RNA in serum, elevations in alanine aminotransferase (ALT) levels, histological evidence of 
progressive liver disease and no other severe co-existing conditions (NIH Consensus 
Statement on Management of Hepatitis C, 2002). Even if today is available treatment cures 
many chronically infected individuals, the treatment has some significant drawbacks. Many 
patients experience severe side effects, such as haematological toxicity, depression, and 
haemolytic anemia, and therapy is expensive (35.000 United State Dollars for 48 weeks 
treatment). Interestingly, both drugs - IFN-α and ribavirin - were not specifically developed 
for the treatment of HCV infection. More recently, novel targets for antiviral drugs have been 
identified in the replication cycle of HCV leading to the development of specifically targeted 
antiviral therapy for HCV (STAT-C). However, this development is still in process and these 
drugs are not yet available on the market. Most importantly, a prophylactic vaccine, which 
would be the most efficient way to prevent HCV-associated liver disease, is not available. 
 
 
Fig. 1.2: Factors affecting the disease progression and response rates to peg-IFN-α and ribavirin 
treatment. 
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1.3  Molecular virology of HCV 
 
1.3.1  Classification 
 
HCV is classified as a member of the Flaviviridae family of viruses, which are associated 
with both human and animal diseases (Miller and Purcell, 1990). The Flaviviridae family 
comprises at least three distinct genera: pestiviruses, which cause disease in the cattle and 
pigs; flaviviruses, which are the most important cause of diseases such as dengue fever and 
yellow fever; and hepaciviruses, which currently includes HCV and GB virus A, B and C 
(Thiel et al., 2005). 
 
1.3.2  HCV replication cycle 
 
HCV virions are enveloped with spherical symmetry and estimated to be 40-50 nm in 
diameter. The envelope contains viral glycoproteins that mediate attachment and entry into its 
host cell. Hepatocytes are the natural targets of HCV. The cell surface receptors that mediate 
viral attachment and entry have been identified. The cluster of differentiation 81 (CD81), the 
scavenger receptor class B member 1 (SR-B1), the tight junction (TJ) proteins Claudin-1 
(CLDN1) and Occludin (OCLN) are sufficient to mediate endocytosis of HCV particles 
(Pietschmann, 2009). Within the cell the nucleopcapsid is released into the cytoplasm. The 
nucleocapsid is round, exhibits polyhedral symmetry (diameter of 25-30 nm) (Büchen-
Osmond, 2003) and contains the HCV-genome. HCV has an RNA genome of positive 
polarity that is approximately 9.6 kb in length. The genome encodes a large polyprotein of 
roughly 3,000 amino acids. The HCV open reading frame (ORF) is flanked by 5´-and 3´-
untranslated regions (UTRs), which are 341 and approximately 230 nucleotides in length, 
respectively (Choo et al., 1991). The 5´and 3´-UTRs are considered important for viral 
translation and replication (Kim et al., 2002). The 5´-UTR consists of four highly structured 
domains and contains the internal ribosome entry site (IRES), which can recruit host factors 
such as the 40S ribosomal subunit and thus initiate the translation of viral proteins 
(Tsukiyama-Kohara et al., 1992). The 3´-UTR consists of stable stem-loop structures and an 
internal poly uracile (U)/polypyrimidine tract. The role that the 3´-UTR have in the regulation 
of the IRES-mediated translation of HCV RNA is not well defined (Murakami et al., 2001; 
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Wang et al., 2005). Several signals essential for RNA replication have been mapped within 
both UTRs (Friebe et al., 2005). 
The polyprotein precursor is co- and posttranslationally processed by both cellular and viral 
proteases at the endoplasmatic reticulum (ER) membrane to yield 10 mature proteins, 
including the structural proteins Core, the envelope proteins E1 and E2, the hydrophobic 
peptide p7 and non-structural proteins (NS2, NS3, NS4B, NS5A and NS5B) (Tellinghuisen 
and Rice, 2002) (Fig. 1.3). The major part of the NS2 protein and the amino-terminal (N-
terminal) part of the NS3 protein form a viral metalloprotease (NS2-3 protease) that cleaves at 
the NS2/3 junction. The cleavage of the remaining non-structural proteins is catalyzed by a 
serine protease (NS3-4A protease) that is a part of the NS3 protein (Hijikata et al., 1993). In 
addition, the carboxy-terminal (C-terminal) domain of NS3 contains sequences for a 
nucleoside triphosphatase (NTPase) and RNA helicases that are considered to regulate the 
replication of viral RNA (Kim et al., 1995). The NS4A polypeptide acts as a cofactor for the 
NS3 serine protease. All HCV proteins are associated to intracellular membranes. The 
processing of the polyprotein occurs at the ER. Moreover, it is currently hypothesized that the 
formation of the membrane-associated viral replication complex occurs at altered cellular 
membranes possibly derived from the ER. NS4B was reported to induce the formation of 
these so-called membranous webs (Gosert et al., 2003). The NS5A varies in size depending 
on GT. This multifunctional protein is highly phosphorylated and associates with membranes 
(Brass et al., 2002). NS5A is also involved in resistance of HCV-infected cells to the antiviral 
activity of IFN-α through repression of the double stranded RNA-dependent protein kinase 
(Gale et al., 1998). A protein binding function for NS5A may have also significant 
implications on roles for NS5A in the switch from genome translation to genome replication 
(Huang et al., 2005). The most C-terminal cleavage product of the viral polyprotein is NS5b, 
the RNA-dependent RNA polymerase (RdRp) responsible for the replication of the HCV 
virus (Behrens et al., 1996). 
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Fig. 1.3: Genome organization of HCV (Chevaliez and Pawlotsky, 2006). 
 
 
1.4 Genetic variability of HCV 
 
HCV exhibits high genetic diversity due to lack a proofreading function of its RdRp. As a 
result, randomly introduced errors in the genome remain uncorrected (Major and Feinstone, 
1997). Many of these mutations are lethal for the virus. Others are silent and therefore neutral 
and some lead to amino acid changes with less prominent effects on viral replication. Thus, 
variants of the HCV genome can evolve rapidly establishing co-existence of several closely 
related but distinct viruses within the same host. This type of viral population is termed 
quasispecies. Viruses within the same quasispecies show 91-99% similarity in the conserved 
genomic regions, but can be distinguished within the more variable regions such as 
hypervariable region 1 (HVR1) and HVR2. The quasispecies nature of HCV enables rapid 
adaptation to changes in the replication environment. In the presence of selection pressure, 
imposed by drugs or by the host immune response, viral variants - that escape from this 
pressure - are selected and outcompete the originally predominant variant.  
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Beyond this sequence diversity between viral variants in the same or between different 
individuals there are more substantial differences between HCV variants at the population 
level. Based on the sequence variability HCV is classified into 7 major genotypes designated 
1 to 7, and so far round 80 subtypes (Fig. 1.4) (Simmonds et al., 2005). Complete genomes 
from different genotypes differ at about 30-35% of nucleotides. Subtypes (of the same GT) 
typically differ at about 20-25% of nucleotides (Simmonds, 2000). Although the clinical 
course of HCV infection does not seem to differ between genotypes, it is important to 
differentiate them as the response to treatment strongly differs. Interestingly, recombinations 
are less frequently observed compared with RNA viruses such as HIV. A few recombinants 
have been described. The first recombination form of HCV containing structural genes from 
subtype 2k and non-structural genes from subtype 1b was found in intravenous drug users 
(IVDUs) in St. Petersburg, Russia (Kalinina et al., 2002). The same recombinant form was 
reported from unrelated individuals originating from Russia and Georgia but resident in 
Ireland at the time of sample collection (Moreau et al., 2006), from HCV chronically infected 
patient in Estonia (Tallo et al., 2007) and from IVDUs in Uzbekistan (Kurbanov et al., 2008). 
Recently other naturally occurring recombinants have been identified, 2i/6p from blood 
donors in Vietnam (Noppornpanth et al., 2006), 2b/1b from patient in Philippines (Kageyama 
et al., 2006) and a 2/5 recombinant from a patient with history of medical interventations in 
France (Legrand-Abravanel et al., 2007). An intragenotype 1a/1b recombinant has also been 
described in patients with chronic hepatic disease in Peru (Colina et al., 2004). However, 
overall these recombination forms seem to be rare. Superinfection or co-infection with two 
different isolates which is the prerequisite for such recombination events are rare even in 
high-risk groups (Viazov et al., 2010).  
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Fig. 1.4: Phylogenetic tree newly classified in seven HCV genotypes. 
 
 
1.5 Epidemiology 
 
Blood transfusions represented the highest risk factor for HCV infection before its discovery 
in 1989. The development of diagnostic tests and establishment of an efficient blood-
screening system has then drastically decreased the incidence of post-transfusion hepatitis in 
developed countries (McHutchison et al., 1998). Blood-screening measures based on the 
detection of HCV antibodies carry a residual risk resulting from a delay of approximately 8-
12 weeks between a possible infection and the generation of antibodies. This diagnostic gap 
after primary HCV infection can be decreased by more sensitive screening methods based on 
polymerase chain reaction (PCR) of HCV-RNA (Fried et al., 2002). Indeed, the residual risk 
of transmitting HCV by blood products is at present estimated at 1/1.000.000 units 
distributed. New cases of HCV infection continue to occur mainly because of IVDU. 
Maternal-fetal transmission is a rare event and mainly seen in mothers who are co-infected 
with HIV-1 (Manns et al., 2001). Current guidelines for pregnant women recommend normal 
childbirth and breast-feeding, both associated with only minimal risk of HCV transmission. 
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Likewise, the sexual transmission of HCV is infrequent but its risk increases upon co-
infection with HIV-1 (Thomas et al., 1998). Nosocomial transmission of the virus is possible 
and includes needle-stick injuries among health care workers, infection during surgery, 
colonoscopy or dialysis. In one third of cases, however, the transmission route of the disease 
remains unclear. 
The distribution of the various genotypes differs by geographic region (Smith and Simmonds, 
1997). Generally, genotypes 1, 2 and 3 are predominantly found in Europe, West-Africa, 
Japan, China, Australia United States and Brazil (Campiotto et al., 2005), while others have a 
more restricted distribution, such as GT4 in the Middle East and Central Africa, GT5a in 
South Africa, and GT6 in Southeast Asia (Bukh et al., 1993). The geographical distribution 
and diversity of HCV genotypes may provide clues regarding the historical origin of HCV 
(Smith and Simmonds, 1997). The high diversity in subtype distribution in some regions of 
the world, as Africa and South-Eastern Asia suggests that HCV has been endemic there since 
long. On the other hand, the lower diversity of subtypes observed in United States and Europe 
may be related to more recent introductions of these subtypes from endemic areas (Pybus et 
al., 2001). Importantly, the GT distribution does not only differ between geographic regions 
but also between risk groups. HCV infection acquired by infusion of contaminated blood 
products are predominantly GT1b whereas GT1a and 3a are more frequently observed in 
IVDUs (Esteban et al., 2008). Consequently, epidemiological data are consistent with a 
decline in circulation of subtype 1b and increase of 1a and 3a infection in Germany, France, 
Norway and United States (Ross et al., 2000). Shift in predominating subtype from 1b to 3a 
mediated by increase in IVDU has been reported (Kalinina et al., 2001).  
 
 
1.6 Risk group of IVDUs 
 
IVDU has become up to now the predominant mode of HCV transmission mechanism of 
HCV in the developed world (Quer and Esteban, 2005). The European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA 2006 report update, available at: 
http://www.emcdda.europa.eu/) and Eurosurveillance (Wiessing, 2005) have estimated a 
median rate of 5.3 IVDUs per 1.000 population aged 16 to 64 (range: 1.1 to 17). IVDU is one 
of the most efficient routes for HCV transmission, which is acquired more rapidly after 
initiation of IVDU than other viral infections, especially during the first year (Sutton et al., 
2006). The pooled prevalence of anti-HCV among IVDUs during the late 1980s and early 
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1990s in Western Europe was 79% (Mathei et al., 2002). Recent estimates have shown a wide 
variation in anti-HCV prevalence among IVDUs in the European Union (EU), with 
prevalence over 60%. Factors associated with an increased risk of HCV infection include age, 
duration and frequency of IVDU, sharing equipment, polydrug use, HCV prevalence among 
experienced IVDUs, homelessness and having served a prison sentence (Hickman et al., 
2007). Differences in the relative contribution of these factors likely explain geographical 
disparities in HCV prevalence. Although harm reduction interventions (i.e. needle-exchange 
and methadone substitution programs) decreased both incidence and prevalence of HCV 
among IVDUs during the 1990s (Roy et al., 2002), HCV transmission among IVDUs remains 
uncontrolled with prevalence increasing among young IVDUs and incidence rates ranging 
between 11 and 42 per 100 person/years (Judd et al., 2005). The worst situation is in Eastern 
Europe where the dramatic IVDU-related HCV epidemic started in the early 1990s and harm 
reduction interventions remain limited (Kalinina et al., 2001; Tallo et al., 2007). Phylogenetic 
analysis of HCV isolates from IVDUs in different European cities shows a typical epidemic 
profile (large number of isolates per subtype, with a short genetic distance) and lack of site-
specific segregation of isolates (Cochrane et al., 2002) suggesting that HCV exchange 
between European IVDUs has occurred on a large scale.  
The IVDU-associated HCV epidemic is having several epidemiological consequences. First, 
most new HCV infections occur in young IVDUs and the proportion of patients with IVDU-
related chronic HCV has surpassed those infected by other routes. Second, IVDU-related 
HCV genotypes (1a, 3a, and 4) have replaced genotypes 1b and 2 among blood donors and 
young patients (Payan et al., 2005). Even among IVDUs, relative GT distribution is rapidly 
changing (Schröter et al., 2004), with GT4 spreading into Central and Northern Europe 
(Payan et al., 2005), and increasing in Southern Europe (Katsoulidou et al., 2006). Third, at 
least one of the recently described intergenotypic HCV recombinants (a 1b/2k) appears to 
have arisen during high-risk IVDU (Kalinina et al., 2002), and is rapidly spreading (Tallo et 
al., 2007). Despite the limited number of recombinants thus far described, the rapid spread of 
the 2k/1b and the generation of further hybrids amidst the IVDU epidemic might limit the 
accuracy of genotyping assays and their predictive value for treatment response (Simmonds et 
al., 2005). Fourth, active HCV infection continues to increase among HIV-infected IVDUs 
(>70%) whose liver disease progresses faster (Martinez-Sierra et al., 2003) and appear more 
resistant to current therapy (Brau, 2005), warranting every effort to provide them with 
optimised treatment strategies (Crespo et al., 2007). Finally, although there is no reliable data 
on the extent to which IVDUs spread HCV over to the general population, strong evidence 
supports that such spread occurs. In Southern Spain, 31% of HCV GT4-infected individuals 
 Introduction 
 11 
have no known risk factor (Fernandez-Arcas et al., 2006). In cohorts of Greek patients with 
chronic HCV, genotypes 3 and 4 were detected in a significant proportion of patients with 
nosocomial or community acquired infection (Katsoulidou et al., 2006). In a French study 
GT3a infection among transfusion recipients increased almost threefold between 1979 and 
1990 (Bourliere et al., 2002). IVDU related subtypes 1a and 3a have been found in a 
substantial proportion of non-IVDU blood donors in the Netherlands and France (van de Laar 
et al., 2006).  
 
 
1.7 Immune response against HCV 
 
Despite a high rate of viral persistence, there is a minority of patients with acute HCV 
infection able to contain virus replication and to achieve sustained eradication of HCV. The 
differences between those patients who achieve control and those who fail to control the 
infection are of utmost interest. It is believed that the virus-specific immune response plays an 
important role in containment of viral replication raising hopes that a vaccine might be 
possible. HCV enters a host either directly through transfusion of contaminated blood 
products or less efficient by perinatal or sexual transmission. The virus reaches the liver via 
the hepatic artery or the portal vein and enters the hepatocytes, its preferred site of replication. 
Once HCV has entered the hepatocyte, the immune response is activated.  
 
1.7.1 Innate immune response 
 
When HCV enters the liver and the infection starts the innate immunity is activated. The 
activation of early type I interferons (IFNs), IFN-α and IFN-β, is an important part in the early 
intracellular defence system against the viral infection. The production of double-stranded 
RNA (dsRNA) intermediates during HCV replication activate type I IFN genes. In 
Chimpanzees already two days after HCV infection large amounts of type I IFNs are 
produced in the liver (Bigger et al. 2001). The host cell recognizes dsRNA either via the Toll 
like receptor 3 (TLR3) (Alexopoulou et al., 2001), or in a TLR-3 independent way. The latter 
pathway represented by the cytoplasmatic sensors of viral RNA, the retinoic acid inducible 
gene-I (RIG-I) (Yoneyama et al., 2004) seems to be particularly relevant in HCV infection. 
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Upon RIG-I activation the IFN-β promoter stimulator 1 (IPS-1) (Kawai et al., 2005) binds to 
the caspase activation and recruitment (CARD) domain of RIG-I and thereby initiates 
activation of IFN regulatory factor 3 (IRF-3) which translocates into the nucleus where it 
induces production of IFN-α/β. The viral dsRNA can also be recognized by TLR3. Activated 
TLR3 recruits Toll/interleukin-1 receptor (TIR) domain (containing adaptor-inducing IFN-β 
also named TRIF), which will lead to downstream activation of nuclear factor kappa B 
(NFκB) and ultimately leading to production of IFN-α/β. IFN-α/β is recognized by type I IFN 
receptor (IFNAR) resulting in a positive feedback loop and activation of multiple IFN-
inducible genes (Hiscott et al., 1999). Examples of these are, protein kinase R (PKR) 
production which leads to block of messenger RNA (mRNA) translation in the infected cell 
(Taylor et al., 1999), and 2’-5’ oligoadenylate synthetases (OAS) that activate the 
endoribonuclease L (RNase L) which in turn degrades RNA in the cell (Taguchi et al., 2004). 
Interestingly, HCV has developed escape strategies that interfere with the activation pathway 
of the innate immune response. For example, the virally encoded NS3/4A protease is able to 
cleave the adapter molecules IPS-1 in the RIG-I pathway and TRIF in the TLR3 pathway, 
thereby preventing the production of type I IFNs within an infected cell. 
At a cellular level, natural killer (NK) and natural killer T (NKT) cells are important players 
in the early response against a viral infection. However, the role of NK cells in control of 
HCV infection is less clear. Khakoo et al. in 2004 described an association between specific 
NK cell receptors and clearance of HCV suggesting that NK cells are important for viral 
containment. NK and NKT cells recognize infected cells in an antigen independent manner 
controlled by activating and inhibiting receptors on the NK cell, or by the interaction between 
CD1 (or other yet unknown ligands) and the T cell receptor on NKT cells, and perform 
cytotoxic lysis of infected cells by releasing granules containing perforin and proteases 
(granzymes). The antigen independent recognition of abnormalities in infected cells, such as 
down regulation of the major histocompatibility complex (MHC) class I molecules, trigger 
the cytolytic activity by the NK cell. NK and NKT cells also produce large amounts of the 
interferon-γ (IFN-γ) cytokine, a potent antiviral and immune regulatory cytokine promoting 
recruitment of inflammatory cells. The production of IFN-γ and tumor necrosis factor-α 
(TNF-α) from NK and NKT cells function as a link between the innate and the adaptive 
immunity by the stimulation of dendritic cell (DC) maturation. This is of vital importance for 
antigen presenting cells (APCs) towards activation of the specific immunity. 
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1.7.2 Adaptive immune response 
 
1.7.2.1 Humoral immune response 
 
Despite the early increase in HCV titer and the induction of IFN-stimulated genes (ISGs), 
delayed immune responses are one of the keys characteristics of HCV infection. HCV-
specific antibodies are detected 8–12 weeks after infection, and HCV-specific T cells are 
typically detectable 8 weeks after infection (Thimme et al., 2002). The role of the humoral 
immune response in HCV infection is still unclear. HCV develops an effective B cell 
response, which is responsible for high titers of specific antibodies. However, in contrast to 
other diseases in which antibodies play an important role to clear the virus by neutralization 
and degradation, in HCV-infection it has been highlighted that most antibodies are unable to 
eliminate the virus (Thimme et al., 2002). Recently tools that are more sophisticated have 
been developed to study the humoral immune response including pseudotyped HCV-like 
particles. These studies concluded that the kinetics of the development of truly neutralizing 
antibodies upon infection plays an important role. The early appearance of antibodies able to 
neutralize the autologous virus seems to be associated with spontaneous control (Pestka et al., 
2007). One important mechanism for viral evasion from a neutralizing antibody response is 
mutational escape. Indeed, the HVR1, which is contained in the N-terminal part of the E2 
protein, is characterized by enormous sequence diversity. This sequence diversity is the result 
of continuous selection of variants that escape from the humoral immune response (von Hahn 
et al., 2007). Interestingly, this region is conserved in patients with agammaglobulinemia 
supporting that immune selection is the major driving force for evolution within this region 
(Booth et al., 1998).  
 
1.7.2.2 Cellular immune response by CD4+ and CD8+ T cells 
 
The decrease in HCV viral load during acute infection coincides precisely with the 
appearance of HCV-specific T cells and IFN-γ expression in the liver (Shin, 2006), which 
suggests that viral clearance is T cell mediated. The importance of both T cell subsets - CD4+ 
and CD8+ T cells - has been elegantly shown by selective depletion experiments in HCV 
infected chimpanzees. Depletion of CD4+ helper T cells led to prolonged viremia associated 
with blunted CD8+ effector T cell responses (Grakoui et al., 2003). Similarly, depletion of 
CD8+ T cells resulted in high-level viremia that was not cleared before CD8+ T cells 
reappeared in the liver at the site of infection (Shoukry et al., 2003). It has not been 
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determined, whether IFN-γ is directly involved in HCV clearance, or whether it is just a 
marker for other T cell functions. Direct antiviral functions would be consistent with the 
observation that IFN-γ-mediated inhibition of subgenomic and genomic HCV RNAs is about 
100 to 1.000 fold more effective than cytotoxicity (Jo et al., 2009).  
In humans, during the acute phase of a HCV infection, it has been shown that strong CD4+ 
and CD8+ T cell responses to HCV antigens are detected in patients who clear the infection as 
compared to those who develop chronic infection (Cucchiarini et al., 2000). When analyzing 
the proliferative CD4+ T cell response in patients with self-limited infection, the immune 
response shows much more vigor compared to the response in chronically infected individuals 
(Missale et al., 1996). Therefore, the induction and maintenance of an HCV-specific CD4+ T 
cell response may be an important factor in the defence against HCV infections. Patients who 
spontaneously cleared HCV infection show a strong and multispecific CD8+ T cell response. 
In contrast, CD8+ T cell responses are typically weak or even absent in patients with chronic 
HCV infection (Lauer et al., 2004). Early studies in patients with acute HCV reported that a 
strong and vigorous CD8+ T cell response is associated with viral clearance (Thimme et al., 
2001). Recent studies suggested that CD8+ T cells are activated during acute HCV infection 
but that these responses are not maintained in those patients who develop chronic infection 
(Bowen and Walker, 2005). The mechanism of CD8+ T cell failure has been extensively 
investigated over the past 10 years. To understand these mechanisms the activation of CD8+ 
T cells needs to be discussed. 
 
 
1.8 Activation of CD8+ T cells 
 
As outlined earlier CD8+ T cells seem to play an important role in clearance of HCV 
infection. This requires activation and recruitment of CD8+ T cells to the site of infection in 
the liver. This activation process is complex and can be dissected into the following steps.  
 
1.8.1 Antigen processing and presentation 
 
The individual cell in the organism necessitates an efficient way to show the surrounding 
immune system whether it has been infected with an intracellular pathogen. The process starts 
with the degradation of the foreign proteins into smaller fragments. This is mediated by the 
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proteasome complex (Seemuller et al., 1996). In order to get recruited to the proteasome 
proteins need to be ubiquitinated (Michalek et al., 1993). Targeted proteins are then unfolded 
and processed in the proteasome to peptides. Proteasome degradation generates peptide 
fragments, which have to be actively transported into the ER where they can associate with 
the relevant MHC class I molecule. This process is mediated by the transporter associated 
with antigen processing (TAP) protein located in the ER membrane (Spies et al., 1990). The 
TAP complex prefers peptides of 8-16 amino acids in length, which is similar to the size of 
peptides binding to MHC class I molecules. There is also a selective translocation determined 
by the peptide sequence and, in particular, the character of its C-terminal residue (Heemels 
and Ploegh, 1994). The MHC class I molecules are assembled in the ER. Upon binding of 
peptide, the peptide/MHC class I complex is released and transported through the Golgi 
apparatus to the cell surface. MHC class I molecules which cannot bind an appropriate 
peptide are unstable and will eventually be translocated into the cytoplasm and degraded by 
the proteasome. The MHC class I molecules are composed of a single membrane-spanning 
heavy chain paired with the soluble light-chain β2m. The heavy chain has a highly 
polymorphic region that forms a cleft where a peptide of 8-10 amino acids in length can bind. 
The most variable residues of the MHC class I molecules point into this groove, conferring 
unique peptide-binding and T cell receptor (TCR)-binding specificity of each MHC class I 
molecule (Maenaka and Jones, 1999).MHC class I molecules are composed by 6 pockets.  
The first and the last are conserved while the intermediates are more varying in size and 
character between different MHC class I alleles, thereby imposing different sequence 
requirements and constraints on the peptide that is bound. One consequence of this is that 
MHC class I binding peptides contain allele-specific sequence motifs (Rothbard and Taylor, 
1988). Predictably, this system of antigen presentations is highly sensitive to variations of the 
peptide antigen. By introducing mutations in an immunogenic peptide or in the flanking 
region of an epitope, the antigen processing and presentation pathway can be affected.  
 
1.8.2 Interaction between CD8+ T cells and peptide/MHC class I complex 
 
CD8+ T cells can interact with the peptide/MHC class I complex via the highly diverse TCR. 
Beyond the characteristics of a peptide that determine the binding affinity to the MHC class I 
molecule the interaction between the peptide/MHC class I complex and the TCR on CD8+ T 
cells is also strongly influenced by the peptide sequence. The TCR contacts the MHC class I 
complex through the TCR variable domains. The affinity between the specific TCR and 
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peptide/MHC class I complex in orders of magnitude is weaker than that of a specific 
antibody–antigen interaction (Matsui et al., 1991). However, because the MHC class I 
molecules serve not only as ligands for the TCR, but also as non-antigen-specific ligands for 
the TCR co-receptors (Gao et al., 1997) - for example, MHC class I molecules for CD8+ T 
cells - even these weak interactions are sufficient to initiate signal transduction in cytotoxic T 
lymphocytes (CTLs).  
The activation of CD8+ T lymphocytes can be divided into two phases, reflecting different 
aspects of the response. In the first phase, naïve cells become activated and differentiate into 
effector cells. In the second phase, the effector cells recognize antigen on specific target cells 
at the site of antigen entry or replication resulting in the destruction of the target cells. 
Depending on the differentiation stage, CTLs may respond with different efficiencies to 
signals mediated by the TCR and, therefore they require different levels of co-stimulatory 
signals for activation. Naïve cells require the signal via the TCR as well as via CD28 and 
additional co-stimulatory signals, while mature effector CTLs only need stimulation through 
the TCR (Schwartz, 1990). CD8+ T cells can be divided into at least 4 different groups, naïve, 
effector, effector memory and central memory. The different states of T cell differentiation 
are associated with distinct functional and phenotypic characteristics. The naïve cells, which 
have yet to encounter their antigen, are continuously recirculating between the secondary 
lymph nodes and the blood stream while the effector and memory cells modulate their 
expression of different homing molecules changing their paths of circulation. The effectors 
are found in inflamed tissues, the spleen, and the liver together with the effector memory 
cells. The circulating pattern of central memory cells more closely resembles that of naïve 
cells, which circulate between the blood stream and the secondary lymph organs (Sallusto et 
al., 1999).  
The ability of naïve T cells to expand and acquire effector functions depends not only on the 
strength of the stimulus through the TCR but also on an array of co-stimulatory receptors 
present on the T cells, such as CD28 (Acuto and Michel, 2003) as well as on soluble factors 
referred to as cytokines (Ahlers et al., 2003). The membrane receptor CD28 has been shown 
to enhance TCR induced proliferation and differentiation of naïve T cells (Shahinian et al., 
1993). These properties have given the receptor the reputation of being the molecule 
responsible for “signal two” in T cells. The two CD28 ligands CD80 and CD86 are expressed 
at high levels on professional APCs (Sharpe and Freeman, 2002). Considerable evidence has 
accumulated to demonstrate that signaling through the TCR and CD28 is not sufficient to 
fully activate naïve CD8+ T cells and support the establishment of a memory population and 
that a third signal is also required. The presence or the absence of IL-12, IFNs, and possibly 
 Introduction 
 17 
IL-21 is a major determinant in whether encounter with foreign antigen leads to CD8+ T cell 
tolerance or immunity. In the absence of this third signal, the antigen-stimulated cells fail to 
develop effector functions, and those that survive long term are tolerant (Mescher et al., 
2006). 
 
 
1.9 Mechanisms of CD8+ T cell failure in HCV infection 
 
As outlined earlier, there is growing evidence that strong and broad HCV-specific CD4+ and 
CD8+ T cell responses are required for viral clearance and protective immunity. For the 
majority of acutely infected patients the infection becomes chronic and CD8+ T cell failure is 
observed (Post et al., 2004). Various mechanisms of CD8+ T cell failure have been described 
(Fig. 1.6). The potential failure mechanisms of CD8+ T cells are described here in more 
detail.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5: Mechanisms of CD8+ T cell failure.  
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1.9.1 Primary CD8+ T cell failure 
 
The T cell response in subjects who spontaneously cleared HCV infection is generally strong 
and multispecific whereas the response is weak or even absent in subjects with chronic 
infection (Lauer et al., 2004). These data were derived in cross-sectional analyses. It is 
therefore not clear whether there is primary failure of CD8+ T cells or secondary failure in the 
chronic phase of infection. One striking feature of the CD8+ T cell response upon acute HCV 
infection is its delayed onset. HCV-specific CD8+ T cells are not detectable until 8 weeks 
after infection (Thimme et al., 2001). It was speculated that DCs as the most important 
professional APCs for CD8+ T cell priming are impaired. However, controversial data have 
been published on this topic including reports showing DCs dysfunction in patients with 
chronic HCV infection (Nettemann et al., 2006) as well as reports showing that DCs function 
is unchanged (Larsson et al., 2004). However, recent data from patients with acute HCV 
infection suggest that the magnitude of the CD8+ T cell response does not differ between 
patients who spontaneously clear the infection and those who continue to viral persistence 
(Cox et al., 2005). In both cases the CD8+ T cells response is strong and multispecific 
suggesting that secondary failure of CD8+ T cells strongly contributes to viral persistence. 
 
1.9.2 The role of the liver as a tolerogenic organ 
 
The liver is the primary replication site of HCV; analyses of liver infiltrating lymphocytes 
(LILs) reveal distinct features from those obtained with peripheral blood mononuclear cells 
PBMCs (Grabowska et al., 2001). The immunological environment in the liver is potentially 
tolerogenic to LILs (Crispe, 2003). Liver sinusoidal endothelial cells, Kupffer cells, stellate 
cells, and liver DCs may mediate this tolerogenic effect (Lau and Thomson, 2003). This has 
not been specifically addressed in the context of HCV infection. However, activation of 
CD8+ T cells in the liver was analyzed in more detail in mouse models. Priming of CD8+ T 
cells in the liver resulted in dysfunctional antigen-specific CD8+ T cells (Diehl et al., 2008). 
Moreover, priming of CD8+ T cells by hepatocytes results in upregulation of pro-apoptotic 
proteins and consequently premature deletion of antigen-specific CD8+ T cells (Holz et al., 
2010). 
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1.9.3 Antigen escape by selection of mutations 
 
Mutations in the epitopes of MHC class I-restricted HCV-specific CD8+ T cells may be one 
important mechanism for failure of a T cell response (Timm and Roggendorf, 2007). The 
presence of quasispecies - a striking feature of HCV - enables the viruses to rapidly adapt to 
immune pressure. It has been observed that mutations in CD8+ T cell epitope regions can 
occur within weeks of acute infection both in chimpanzees and in men (Erickson et al., 2001; 
Timm et al., 2004; Tester et al., 2005; Cox et al., 2005). T cell escape mutations 
predominantly occur during early infection, and no additional mutations are observed during 
several years of subsequent follow-up (Chang et al., 1997). Adaptation of HCV to T cell 
immune pressure was also observed at a population level data (Timm et al., 2007; Ray et al., 
2005). Lack of CD4+ T cell help was associated with emergence of viral escape mutations 
(Grakoui et al., 2003). Mechanistically escape mutations can be classified into those that 
cause (1) lower binding affinity of epitope peptide to MHC class I molecule (Tester et al., 
2005); (2) decreased TCR recognition of mutant peptides (Timm et al., 2004); (3) impaired 
antigen processing by proteasomes (Seifert et al., 2004). It is unclear to what extent selection 
of escape mutations contributes to viral persistence. In an analysis of the intrahepatic CD8+ T 
cell response about 50% of the targeted epitopes show evidence for escape. The remaining 
50% are intact and recognized by circulating CD8+ T cells. Therefore, selection of escape 
mutations is clearly not the only factor involved in HCV persistence and T cell failure. 
 
1.9.4 T cell dysfunction and exhaustion 
 
It was described in several reports that effector functions of CD8+ T cells are impaired during 
acute and chronic HCV infection (Lechner et al., 2000; Wedemyer, 2002). By means of 
tetramer, Elispot, ICS, and FACS technologies, defective HCV-specific CD8+ T cells in 
frequency, proliferation, cytotoxicity, and secretion of TNF-a and IFN-γ have been observed. 
The anergic CD8+ T cells are referred as stunned phenotype (Wedemeyer, 2002). T cell 
dysfunction was identified not only in chronic (Spangenberg et al., 2005), but also in acute 
HCV infection (Thimme et al., 2001), including both CD8+ (Wedemeyer, 2002) and CD4+ T 
cells (Cucchiarini et al., 2000) from PBMCs (Penna et al., 2007) and the liver (Wieland and 
Chisari, 2005). This T cell exhaustion can now be addressed since specific markers became 
available. Programmed death 1 (PD-1) is a strong marker for exhausted virus-specific CD8+ 
T cells in the lymphocytic choriomeningitis virus (LCMV) mouse model, and a similar role 
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for PD-1 has been shown in HCV infection. During the acute phase of an HCV infection, 
similar to an LCMV infection, PD-1 is upregulated in HCV-specific CD8+ T cells, 
independent of the outcome (Radziewicz et al., 2007). However, in individuals with resolving 
infection, the PD-1 expression decreases rapidly, while in patients with a chronic infection, 
HCV-specific CD8+ T cells remain PD-1 positive (Urbani et al., 2006). This finding is in 
parallel with the ‘‘stunned’’ phenotype of HCV-specific CD8+ T cells in the early acute phase 
of infection, which is restored in resolving infection but remains in persisting infection. In 
chronic HCV infection, HCV-specific CD8+ T cells in the peripheral blood and in the liver 
have been shown to express high levels of PD-1 (Wieland and Chisari, 2005). Inhibition of 
the PD-1/PD ligand 1 (PD-L1) interaction by antibodies restored cytokine production and 
proliferation of the exhausted CD8+ T cells from both acute and chronic infection in vitro 
(Golden-Mason et al., 2007). In contrast to those in the periphery, intrahepatic HCV-specific 
T cells compartmentalized to liver, express not only high levels of PD-1 but also decreased 
CD127, were extremely refractory to PD-1/PD-L1 blockade (Nakamoto et al., 2008). 
 
1.9.5 Suppression by regulatory T Cells 
 
Different subsets of regulatory T (Treg) cells contribute to the dysfunction of virus-specific T 
cells and thus to the HCV persistence. The frequencies of CD4+CD25+FoxP3+Treg and 
CD8+CD25+FoxP3+Treg in the periphery of HCV-infected patients are reported to be higher 
than those in resolved patients or uninfected controls (Billerbeck and Thimme, 2008). In 
addition, these cells inhibit HCV-specific CD8+ and CD4+ T cells by secreting IL-10 and 
transforming factor beta (TGF-β) (Sugimoto et al., 2003). It was found that the frequency of 
CD4+CD25+ T cells and the HCV RNA titer is positively correlated. CD8+CD197- 
regulatory T cells are present in the HCV-infected liver, these cells are capable of suppressing 
HCV-specific CD8+ T cells by secreting IL-10, thus favouring HCV persistence and limited 
liver injury (Accapezzato et al., 2004). Rosen’s group in 2008 demonstrated that FoxP3 
expression levels and Treg-mediated suppression in the acute phase of HCV infection do not 
differ between patients who subsequently clear HCV and those who develop chronic infection 
(Smyk Pearson et al., 2008), suggesting that Tregs are induced as a result of acute 
inflammation. 
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1.10 Evidence for protective immunity against HCV 
 
The degree of possible HCV cross-protective immunity against homologous or heterologous 
HCV strains has been addressed in a number of observational and experimental studies both 
in humans (Proust et al., 2000; Mehta et al., 2002) and chimpanzees (Landfrod et al., 2004). 
In chimpanzees, repetitive infections with HCV are possible. This was mostly evident when 
animals were infected with different HCV genotypes raising concerns that protective 
immunity will be difficult to achieve in the context of a pathogen with such dramatic 
sequence variability. However, observational studies in high-risk groups for HCV infection 
suggested that previous exposure to HCV at least provides partial protection from re-
infection. In 2002, Mehta et al. reported that previously infected IVDUs were significantly 
less likely to be reinfected, even after accounting for risk behavior. Further reports supported 
this finding: Grebely et al. in 2006 reported a significantly lower incidence of HCV 
reinfection in IVDUs than in naïve individuals; and Dove et al in 2005 detected no 
reinfections in a small group of ongoing IVDUs with previous HCV clearance. These findings 
suggest that human beings can acquire protective immunity as has been shown in 
chimpanzees (Basset et al., 2001). This degree of protection is unclear after previous HCV 
infection is unclear. Other studies in chimpanzees have instead demonstrated a relative lack of 
protection against rechallenge with heterologous virus strains, indicating poor cross-GT 
recognition (Prince et al., 2005). Schulze Zur Wiesch et al., in 2007 showed that persistent 
HCV-specific CD4+ T cell responses detected in a subset of chronically infected patients are 
unable to recognize the contemporary circulating viruses, likely representing immunologic 
scars from a previously resolved HCV infection. Only few data on the role of preexisting T 
cell responses on the outcome of a subsequent HCV infection are available. Interesting 
insights in this direction came in 2006 from Folgori et al., they showed that vaccination with 
adenoviral vectors in combination with electroporated deoxyribonucleic acid (DNA) coding 
for the HCV non-structural region is able to protect chimpanzee from acute hepatitis. The 
challenge in this case was performed with a heterologous virus differing from the vaccine 
sequence by more than 13% at the amino acid level, and all vaccinated chimpanzees that 
developed a cross-reactive T cell response against the challenge virus (4 of 5) were capable of 
resolving the infection (Folgori et al., 2006). No data on this topic are available in humans. 
Importantly, the relevance of GT-specific sequence differences on the CD8+ T cell response 
and the level of protection in humans are completely unknown. IVDUs being highly 
susceptible to reinfection represent a perfect model for studying the impact that multiple 
exposures to different genotypes may have on the immune system. In the present work, the 
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CD8+ T cell responses to HCV were therefore studied in more detail recruiting IVDUs from 
the Department of Addictive Behaviour and Addiction Medicine, Rhine State Hospital Essen. 
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2 Aims of the study 
 
The overall aim of this study is to characterize the CD8+ T cell response in IVDUs 
representing a high-risk group for HCV infection that is possibly exposed multiple times to 
different HCV genotypes.  
The following questions are specifically addressed: 
1. What is the extent of sequence differences between the most common HCV genotypes 
in IVDUs (GT1 and 3) at the CD8 epitope level? 
2. What is magnitude and breadth of the CD8+ T cell response against HCV GT1 and 
GT3 in this high-risk group? 
3. What are the consequences of sequence differences between HCV GT1 and 3 for the 
CD8+ T cell response at the epitope level? 
4. Is there immunological evidence for exposure to different HCV genotypes in 
individual patients? 
5. Are there phenotypic differences in the CD8+ T cell epitope repertoire of patients who 
control virus replication compared to patients with ongoing virus replication? 
6. Are there qualitative differences between CD8+ T cells from patients who control 
virus replication compared to patients with ongoing virus replication? 
7. Is it possible to prime naïve CD8+ T cells against immunodominant HCV epitopes? 
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3 Materials 
 
3.1 Equipment  
 
Table 3.1: Equipment 
 
Item Manufacturer 
AutoMACS Pro Separator Miltenyi Biotec (Ger) 
Binders CB Series CO2 Incubators Binder USA 
Centrifuge 5415 D Eppendorf (Ger) 
Elisa Reader A Sys Expert Plus Asys Hiteck Gmbh (Aus) 
FACS calibur flow cytometer BD (Ger) 
Freezer Liebherr (Ger) 
GeneAmp PCR System 2400 Applayed Biosystems (Ger) 
Inverted Microscope TMS Nikon Nikon (Ger) 
Laminar flow Herasafe (Ger) 
Mastercycler Personal Eppendorf (Ger) 
Megafuge 1,0 R Heraeus (UK) 
Metall-Block-Thermostate MBT 250 Kleinfeld Labortechnik (GER) 
Neubauer cell counting chamber BD (Ger) 
Photometer Gene Quant Amersham Bioscience Europe Gmbh (Ger) 
Refrigerator Premium (Ger) 
Ultra-low Temperature Freezer Sanyo (Ger) 
UV transluminator FLX-20M MWG-Bio Tech (Ger) 
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3.2 Materials 
 
Table 3.2: Materials 
 
Material Manufacturer 
Beakers Beakers Schott (Ger) 
Cell culture plates, sterile (6; 24 and 96 well) Greiner bio-one (Ger) 
FACS tubes BD (Ger) 
Plastic pipettes (sterile; 1 ml; 5 ml; 10 ml; 25 ml)  Greiner bio-one (Ger) 
PP screw-cap tubes (15 ml; 50 ml)  Greiner bio-one (Ger) 
Reaction tubes (1,5 ml; 2 ml)  Eppendorf AG (Ger) 
U-shaped microplates (96 wells)  Greiner bio-one (Ger) 
2 ml, 1.5 ml and 0.2 ml tubes  Eppendorf AG (Ger) 
 
3.3 Chemicals and Media 
 
Table 3.3: Chemicals and Media 
 
Chemicals and Media Manufacturer 
Biocoll separating solution 1.10 Biochrom (Ger) 
Brefeldin A BD (Ger) 
CellGro Medium CellGenix (Ger) 
Cytofix/Cytoperm BD Pharmingen (Ger) 
DMSO (Dimethyl sulfoxide) ROTH GmbH (Ger) 
EDTA Ambion (UK) 
Ethanol ROTH GmbH (Ger) 
Ethidium bromide ROTH GmbH (Ger) 
FCS (Fetal calf serum) Biochrom 
HEPES PAA Laboratories (Ger) 
Isopropanol ROTH GmbH (Ger) 
Lipopolysaccharides (LPS) Sigma Aldrich Chemie GmbH (Ger) 
RPMI 1640 Medium Gibco (Ger) 
Smart ladder  Eurogentec (Ger) 
Sodium Azide Applichem (Ger) 
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Chemicals and Media           Manufacturer 
Tris-Borate-EDTA (TBE) Invitrogen GmbH (Ger) 
Via-Probe Cell Viability solution BD (Ger) 
 
3.4 Enzimes 
 
Table 3.4: Enzymes 
  
Enzymes Supplier 
Protease (protienase K) QIAgen (Ger) 
Go Taq Polymerase Promega (Ger) 
Dnase I Roche (Ger) 
 
3.5 Cytokines 
 
Table 3.5: Cytokines 
 
Cytokines Manufacturer 
Recombinant Human Interleukine-2 (rHu IL-2) Promokine (Ger) 
Recombinant Human Interleukine-4 (rHu IL-4) Promokine (Ger) 
Recombinant Human Interleukine-7 (rHu IL-7) Promikine (Ger) 
Recombinant Human Interleukine-15 (rHu IL-15) Promokine (Ger) 
Recombinant Human Granulocyte and Macrophage 
Colony Stimulating Factor (rHu GM-CSF) 
Promokine (Ger) 
 
Recombinat Human Intereferon-gamma  
(rHu IFN-γ) 
Promokine (Ger) 
 
 
 
 
 
 
 
 
 Materials 
 27 
 
3.6 Commercial Kits 
 
Table 3.6: Commercial Kits 
 
 
 
3.7 Antibiotics 
 
Gentamicin PAA Laboratories GmbH (Ger) 
Penicillin / Streptomycin PAA Laboratories GmbH (Ger) 
 
 
3.8 Buffers and Media 
 
Table 3.7: Buffers and Media 
 
Description Composition 
DCs culture medium 
500 ml  
10% Human serum 
1% Gentamicin 
2000 IU/ml IL-4 
2000 IU/ml GM-CSF 
  
Co-culture medium 
500 ml RPMI 1640 
10% FCS 
1% Penicillin/Streptomycin mixture 
1% Hepes 
  
Cytokines Manufacturer 
QIAmp Viral RNA Mini Kit 250 QIAgen GmbH (UK) 
QIAGEN OneStep RT-PCR Kit QIAgen GmbH (UK) 
QIAQuick Gel extraction Kit QIAgen GmbH (UK) 
QIAamp DNA Blood Mini KIT50 QIAgen GmbH (UK) 
Murex HCV Serotyping Abbott Murex (UK) 
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Description Composition 
Freezing medium 
 
90% FCS 
10% DMSO 
  
PBMCs culture medium 
500 ml RPMI 1640 
10% FCS 
1% Penicillin/Streptomycin mixture 
1% Hepes 
IL-2 2.5 μl/ml 
CD28 μl/ml 
  
FACS buffer  
1 l PBS 
0.02% Na-azide 
0.5% FCS 
  
MACS buffer 
1 l PBS 
2mM EDTA 
0.5% FCS 
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3.9 Oligonucleotides 
 
All the oligonucleotides used in this work have been synthesized by Biomers net GmbH 
(Ulm). In the following list are mentioned only primers used for the amplification of different 
HCV genome’s regions. 
 
Table 3.8: Oligonucleotides 
 
Genotype Primer Sequences 
Targeted 
region 
 p439s 5’-GAGTWTACBTGYTGCCGCGCAG-3’ Core 
GT1b SV963s_neu 5’-CTACCCGTCTCCGCCCGVAGR-3’ NS3 
GT1b NS3-1113-R 5’-CTTGGAGTGRCAGAAAATGAG-3’ NS3 
GT1b SV694as_neu 5’-ATCCTRCCCACAATGACCACR-3’ NS3 
GT1b HCV3404s_neu 5’-AGGGTGGCGACTCCTYGCK-3’ NS3 
GT1b Anti-D_NS3-913-F 5’-ACRGTCCTGGACCAAGCR-3’ NS3 
GT1b NS3-1058-R 5’-GCYTTRCCATAGAAGGGRA-3’ NS3 
GT1b SV696as 5’-GCCCACAATGACCACGCTGCC-3’ NS3 
GT1b GT1b-3c-R 5’-CCAARTAAAGGTCCGAGCTGCC-3’ NS3 
GT1b GT1b-3e-R 5’-CGCCCGTGGTGATGGTCC-3’ NS3 
GT1b GT1b-4c-F 5’-CTATGGCAAAGCCATCCC-3’ NS3 
GT1b GT1b-4b-R 5’-CATTAGAGCGTCTGTTGC-3’ NS3 
GT1b GT1b-4d-F 5’-GCATMTACAGGTTTGTGACTCC-3’ NS3 
GT1a 3b-F 5’-TGGRTTCCCCCCCTCAACG-3’ NS3 
GT1a 4a-R 5’-TCTCCGGTGGTGGACAGAGC-3’ NS3 
GT1a 4a-F 5’-AGTGCCCCAGAGCTTCCAGG-3’ NS3 
GT1a 4e-R 5’-GGGCCCTTCTGCTTGAACTGC-3’ NS3 
GT1a 3c-F 5’-TCCRAATGGAGACCAAGC-3’ NS3 
GT1a 3e-R 5’-CGCCCGTGGTGATGGTCC-3’ NS3 
GT1a 4b-F_new 5’-GTAARAGCACCAAGGTYCC-3’ NS3 
GT1a 4d-R 5’-ACCCAGGTGCTCGTGACG-3’ NS3  
GT1a 4b-F 5`-AAGGACCATCACCACGGG -3` NS3 
GT3a 3256-F 5’-CTAGCAGTGGCCACTGAACC-3’ NS3 
GT3a 4577-R 5’-GTTGAGCCCCATRCCTCTRA-3’ NS3 
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Genotype Primer Sequences 
Targeted  
region 
GT3a 4294-F 5’-ATTATCTGTGATGARTGYCATGC-3’ NS3 
GT3a 5452-R 5’-TATTGTTGRTACARCACCTC-3’ NS3 
GT3a 3341-F 5’-ATATTCTTTGCGGGCTGC-3’ NS3 
GT3a 4460-R 5’-GGGATCTCACCTTCRGARC-3’ NS3 
GT3a 4328-F 5’-CTAGCATAYTGGGYATAGGCAC-3’ NS3 
GT3a 5439-R 5’-CACCTCYTTRTCTGGAACG-3’ NS3 
GT3a 3341-F 5’-ATATTCTTTGCGGGCTGC-3’ NS3 
 
 
3.10 Peptides 
 
a. List of overlapping and optimal peptides used in the preliminary screening of the 
immune responses of the IVDUs (from Filiz Oezkan, Department of Dermatology, 
University Hospital St. Josef, Bochum, Germany). 
 
Table 3.9: Peptides 
 
Group Name GT1b  GT3a  
Pool 1 1 APITAYSQQTRGLLGCII APITAYAQQTRGLLGTIV 
 2 SQQTRGLLGCIITSLTGR AQQTRGLLGTIVTSLTGR 
 3 GCIITSLTGRDKNQV GTIVTSLTGRDKNVV 
 4 SLTGRDKNQVEGEVQVV SLTGRDKNVVTGEVQVL 
 5 NQVEGEVQVVSTATQSFL NVVTGEVQVLSTATQTFL 
 6 VVSTATQSFLATCVNGVC VLSTATQTFLGTTVGGVM 
 7 FLATCVNGVCWTVYHGA FLGTTVGGVMWTVYHGA 
 8 GVCWTVYHGAGSKTLAGP GVMWTVYHGAGSRTLAGA 
 9 GAGSKTLAGPKGPITQMY GAGSRTLAGAKHPALQMY 
Pool 2 10 GPKGPITQMYTNVDQDLV GAKHPALQMYTNVDQDLV 
 11 MYTNVDQDLVGWQAPPGA MYTNVDQDLVGWPAPPGA 
 12 LVGWQAPPGARSLTPCT LVGWPAPPGAKSLEPCA 
 13 PGARSLTPCTCGSSDLYL PGAKSLEPCACGSADLYL 
 14 CTCGSSDLYLVTRHADVI CACGSADLYLVTRDADVI 
 Materials 
 31 
 
Group Name GT1b GT3a 
 15 YLVTRHADVIPVRRR YLVTRDADVIPARRR 
 16 HADVIPVRRRGDSRGSLL DADVIPARRRGDSTASLL 
 17 RRGDSRGSLLSPRPVSYL RRGDSTASLLSPRPLACL 
 18 LLSPRPVSYLKGSSGGPL LLSPRPLACLKGSSGGPV 
Pool 3 19 YLKGSSGGPLLCPSGHAV CLKGSSGGPVMCPSGHVA 
 20 PLLCPSGHAVGIFRAAV PVMCPSGHVAGIFRAAV 
 21 HAVGIFRAAVCTRGVAKA HVAGIFRAAVCTRGVAKA 
 22 AVCTRGVAKAVDFVPV AVCTRGVAKALQFIPV 
 23 VAKAVDFVPVESMETTMR VAKALQFIPVETLSTQAR 
 24 PVESMETTMRSPVFTDNS PVETLSTQARSPSFSDNS 
 25 MRSPVFTDNSSPPAV ARSPSFSDNSTPPAV 
 26 FTDNSSPPAVPQTFQVAH FSDNSTPPAVPQSYQVGY 
 27 AVPQTFQVAHLHAPTGSGK AVPQSYQVGYLHAPTGSGK 
Pool 4 28 HLHAPTGSGKSTKVPAAY YLHAPTGSGKSTKVPAAY 
 29 GKSTKVPAAYAAQGYKVL GKSTKVPAAYVAQGYNVL 
 30 AYAAQGYKVLVLNPSVAA AYVAQGYNVLVLNPSVAA 
 31 VLVLNPSVAATLGFGAYM VLVLNPSVAATLGFGSFM 
 32 AATLGFGAYMSKAHGV AATLGFGSFMSRAYGI 
 33 GAYMSKAHGVDPNIR GSFMSRAYGIDPNIR 
 34 KAHGVDPNIRTGVRTI RAYGIDPNIRTGNRTV 
 35 PNIRTGVRTITTGAPITY PNIRTGNRTVTTGAKLTY 
 36 TITTGAPITYSTYGKFLA TVTTGAKLTYSTYGKFLA 
Pool 5 37 TYSTYGKFLADGGCSGGA TYSTYGKFLADGGCSGGA 
 38 LADGGCSGGAYDIII LADGGCSGGAYDVII 
 39 CSGGAYDIIICDECHS CSGGAYDVIICDECHA 
 40 DIIICDECHSTDSTTIL DVIICDECHAQDATSIL 
 41 CHSTDSTTILGIGTVL CHAQDATSILGIGTVL 
 42 TTILGIGTVLDQAETAGA TSILGIGTVLDQAETAGV 
 43 VLDQAETAGARLVVLATA VLDQAETAGVRLTVLATA 
 44 GARLVVLATATPPGSVTV GVRLTVLATATPPGSITV 
 45 TATPPGSVTVPHPNIEEV TATPPGSITVPHSNIEEV 
Pool 6 46 TVPHPNIEEVALSNTGEI TVPHSNIEEVALGSEGEI 
 47 EVALSNTGEIPFYGKAI EVALGSEGEIPFYGKAI 
 48 GEIPFYGKAIPIEVIK GEIPFYGKAIPIALLK 
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Group Name GT1b GT3a 
 49 GKAIPIEVIKGGRHLIF GKAIPIALLKGGRHLIF 
 50 VIKGGRHLIFCHSKKK LLKGGRHLIFCHSKKK 
 51 HLIFCHSKKKCDELAAKL HLIFCHSKKKCDEIASKL 
 52 KKCDELAAKLSALGLNAV KKCDEIASKLRGMGLNAV 
 53 KLSALGLNAVAYYRGLDV KLRGMGLNAVAYYRGLDV 
 54 AVAYYRGLDVSVIPTSGDV AVAYYRGLDVSVIPTTGDV 
 55 VSVIPTSGDVVVVATDAL VSVIPTTGDVVVCATDAL 
Pool 7 56 DVVVVATDALMTGYTGDF DVVVCATDALMTGFTGDF 
 57 ALMTGYTGDFDSVIDCNT ALMTGFTGDFDSVIDCNV 
 58 DFDSVIDCNTCVTQTVDF DFDSVIDCNVAVEQYVDF 
 59 NTCVTQTVDFSLDPTFTI NVAVEQYVDFSLDPTFSI 
 60 DFSLDPTFTIETTTV DFSLDPTFSIETRTA 
 61 PTFTIETTTVPQDAVSR PTFSIETRTAPQDAVSR 
 62 TTVPQDAVSRSQRRGR RTAPQDAVSRSQRRGR 
 63 AVSRSQRRGRTGRGRR AVSRSQRRGRTGRGRL 
 64 RRGRTGRGRRGIYRFVT RRGRTGRGRLGTYRYVA 
 65 GRRGIYRFVTPGERPSGM GRLGTYRYVAPGERPSGM 
Pool 8 66 VTPGERPSGMFDSSVL VAPGERPSGMFDSVVL 
 67 PSGMFDSSVLCECYDA PSGMFDSVVLCECYDA 
 68 SSVLCECYDAGCAWYEL SVVLCECYDAGCSWYDL 
 69 YDAGCAWYELTPAETSVR YDAGCSWYDLQPAETTVR 
 70 ELTPAETSVRLRAYL DLQPAETTVRLRAYL 
 71 ETSVRLRAYLNTPGLPV ETTVRLRAYLSTPGLPV 
 72 AYLNTPGLPVCQDHLEFW AYLSTPGLPVCQDHLDFW 
 73 PVCQDHLEFWESVFTGL PVCQDHLDFWESVFTGL 
 74 EFWESVFTGLTHIDAHFL DFWESVFTGLTHIDAHFL 
 75 GLTHIDAHFLSQTKQAGD GLTHIDAHFLSQTKQQGL 
Pool 9 76 FLSQTKQAGDNFPYLVAY FLSQTKQQGLNFSYLTAY 
 77 GDNFPYLVAYQATVCARA GLNFSYLTAYQATVCARA 
 78 AYQATVCARAQAPPPSW AYQATVCARAQAPPPSW 
 79 ARAQAPPPSWDQMWKCLI ARAQAPPPSWDETWKCLV 
 80 SWDQMWKCLIRLKPTLH SWDETWKCLVRLKPTLH 
 81 CLIRLKPTLHGPTPLLYR CLVRLKPTLHGPTPLLYR 
 82 LHGPTPLLYRLGAVQNEV LHGPTPLLYRLGPVQNEI 
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Group Name GT1b GT3a 
 83 YRLGAVQNEVTLTHPITK YRLGPVQNEICLTHPVTK 
 84 EVTLTHPITKYIMACMSA EICLTHPVTKYIMACMSA 
 85 TKYIMACMSADLEVVT TKYIMACMSADLEVTT 
OPT 1 1 ATDALMTGY  
 2 HSKKKCDEL  
 3 HPNIEEVAL  
 4  CVNGVCWTV 
 5 KLVALGINAV  
OPT 2 1 AYSQQTRGL  
 2 MYTNVDQDL  
 3 YLVTRHADV  
 4 HAVGLFRAA  
 5 TLGFGAYMSK  
 6 ALYDVVTKL  
OPT 1 1 GAYMSKAHGV  
 2 GRGKPGIYR  
 3 KSKKTPMGF  
 4 ARMILMTHF  
 5 NTRPPLGNW  
Control Flu GILGFVFTL  
 
 
b. List of peptides identified during the MHC class I binding prediction analyses and 
used to identify the epitope specific responses (EMC, Ger). 
 
Name Sequence Genotype HLA restriction 
p23 HSNIEEVAL 3a B35 
p24 CINGVCWTV 1b prototype A2 
p25 TVGGVMWTV 3a A2 
p26 KAVDFVPVE 1b A26 
 p27 FVPVESMET 1b/3a A26 
p28 VDFVPVESM 1b/3a A3 
p29 VESMETTMR 1b/3a B40 
p30 ETTVRLRAY 1b/3a A26 
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Group Name GT1b GT3a 
p31 ETSVRLRAY 1b/3a A26 
p32 RLGAVQNEV 1b A2 
p33 RLGPVQNEI 3a A2 
p34 VTLTHPITK 1b A3 
p35 VQNEICLTH 3a B15 
p36 NEICLTHPV 3a A3 
p37 KAHGVDPNI 3a A2 
p38 HLHAPTGSGK 1b A3 
p39 GSFMSRAYGI 3a A3 
p40 GLNAVAYYR 3a A3 
p41 KLSGLGINAV 1b variant A2 
p42 KLSGLGLNAV 1b variant A2 
p43 KLSALGLNAV 1b  A2 
p44 KLRGMGLNAV 3a A2 
p46 HSRRKCDEL 3a B8 
p47 ALYDVVTKL 1b A2 
p48 RLGAVQNEA 1b B13 
p49 RLGPVQNEV 3a B13 
p50 RLGAVQNEI 1b variant B13 
p51 HSKKKCDDL 1b variant B8 
p48 1073 CINGVCWSV 1a variant A2 
p49 1073 CINGVCWAV 1a variant  A2 
p50 HAVGIFRAAV 1a/b A68 
p51 HAVGIFKAAV 1a/b variant A68 
p52 HAVGIFQAAV 1a/b variant A68 
p53 HAVGIFRTAV 1a/b variant A68 
p54 RRGRTGRGRL 3a B27 
p55 RRGRTGRGRR 1b B27 
p56 GRGRLGTYRY 3a B27 
p57 GRGRRGIYRF 1b B27 
p58 GRGKPGIYRF 1a B27 
p59 YLHAPTGSGK 3a A3 
p60 GEIPFYGKAI 1b/3a B51 
p61 LIRLKPTL 1b B8 
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Name Sequence Genotype HLA restriction 
p62 LVRLKPTL 3a B8 
p63 HSKKKCDEI 3a B8 
p64 HVAGIFRAAV 3a A68 
p65 TYSTYGKFL 1b/3a A24 
p66 GIDPNIRTGV described A2 
p67 GVDPNIRTGV 1b A2 
p68 GIDPNIRTGN 3a A2 
 
3.11 Antibodies 
 
Unless otherwise noted, the antibodies were procured from BD, Germany. 
 
Table 3.10: Antibodies 
 
Antibodies  Clone 
BimS/EL/L: monoclonal rat anti-human antibody (Rat IgG2a) [Alexis] 3C5 
CD8-PE: monoclonal mouse anti-human antibody (IgG1, k) HIT8a 
CD8-APC: monoclonal mouse anti-human antibody (IgG1, k) RPA-T8 
CD14-PE: monoclonal mouse anti-human antibody (IgG2a, k)  M5E2 
CD14 monoclonal mouse anti-human antibody (IgG2a) conjugated  
MicroBeads [Miltenyi Biotec] 
TÜK4 
 
CD28 / CD49d: monoclonal mouse anti-human antibodies L293, L25 
CD80(B7-1)-FITC: monoclonal mouse anti-human antibody (IgM, k)  BB1 
CD127(IL-7Ra)-FITC: monoclonal mouse anti-human antibody (IgG1) 
[eBioscience] 
eBioRDR5 
 
HLA-A2-FITC: monoclonal mouse anti-human antibody (IgG2b, k) BB7.2 
IFNγ-FITC: monoclonal mouse anti-human antibody (IgG1, k) 4S.B3 
IFN-γ APC: monoclonal mouse anti-human antibody (IgG1, k) B27 
Rat IgG2a-FITC: polyclonal goat anti rat antibody [Bethyl] 
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3.12 Fluorochromes 
 
The antibody-coupled fluorochromes and their absorption- and emission maxima are listed 
below. 
 
Table 3.11: Fluorochromes 
 
Flurophore Abbreviation Absorption (nm) Emission (nm) 
Fluorescein  isothiocyanate FITC 488 518 
Phycoerythrin PE 488 575 
Peridinin-chlorophyll-protein 
complex 
PerCP 
 
488 
 
675 
 
Allophycocyanin APC 633 660 
 
3.13 MHC class I-Pentamers 
 
Table 3.12: MHC class I-Pentamers 
 
 
 
 
 
 
 
 
 
HLA type Sequence Epitope Origin Virus Label 
A2 GILGFVFTL 
 
Influenza A 
MP 58-66 
Influenza PE 
A2 CINGVCWTV HCV 
NS3 1073-1081 
HCV PE 
A2 KLVALGINAV HCV 
NS3 1406-1415 
HCV PE 
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3.14 Computer programs 
 
Table 3.13: Computer programs 
 
Software Manufacturer 
Cell quest  BD 
CodonCode Aligner CodonCode Corporation 
Flowjo TreeStar Inc. 
Graphpad Prism Graphpad 
Microsoft Office Microsoft 
 
3.15 Websites 
 
HCV Sequence Database (http://hcv.lanl.gov/) 
Immune Epitope Database and Analysis resource (http://www.iedb.org/) 
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4 Methods 
 
4.1 Patients 
 
Patients with a history of IVDU who reported to be HCV-positive were recruited in the ward 
for inpatient detoxification treatment of drug addicts as well as in the clinic for opiate 
substitution treatment (OST) at the Department of Addictive Behaviour and Addiction 
Medicine, Rhine State Hospital Essen, University of Duisburg-Essen after written informed 
consent was obtained. By this approach 53 anti-HCV positive patients (identified by 
chemiluminescent microparticle immunoassay, CMIA) were identified including 17 infected 
with GT1, 22 infected with GT3 and 14 HCV-RNA negative subjects. The Glutamic-Pyruvic 
Transaminase (GPT) levels, the viral load and the serotype of the autologous virus were 
analyzed in all occasions. The study was approved by the local ethics committee according to 
the guidelines of Helsinki.  
 
 
4.2 Extraction of viral RNA 
 
HCV-RNA was extracted from patient’s serum by using a QIAamp Viral RNA mini Kit. As 
shown in the manufacturer’s instructions, 140 μl of serum were added to the lysis buffer (200 
μl AVL buffer) into a 1.5 ml microcentrifuge tube then incubated for 10 min at room 
temperature (RT) (15–25°C). The lysate was mixed with 560 μl of 100% ethyl alcohol 
(EtOH), then transferred to the QIAamp Mini column and centrifuged for 1 min at 8000 rpm. 
The column was washed with 500 μl of AW1 and 500 μl of AW2 buffers. The viral RNA was 
eluted in 50 μl of water in new 1.5 ml microcentrifuge tube and directly used in the reverse 
transcription reaction or kept at - 80°C. 
 
 
4.3 Reverse transcriptase reaction 
 
HCV-RNA isolated from patient’s serum was reverse transcribed into DNA using OneStep 
reverse transcriptase (RT-PCR), 5 μl extracted RNA was added to the following: 
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One Step RT-PCR Mix 
 
5x Buffer 
 
5 μl 
 
Water (H2O) 
 
11 μl 
 
RT-PCR Enzyme Mix 
 
1 μl 
 
Forward-Primer1 (10 pmol/μl) 
 
1 μl 
 
Reverse-Primer1 (10 pmol/μl) 
 
1 μl 
 
Deoxynucleosides (dNTPs, 10 mM) 
 
1 μl 
 
Total 
 
20 μl 
 
 
 
Thermal cycling 
 
45 min  50º 
15 min  94º 
1 min  94º 
1 min  54º 
1 min/kb  72º 
Cycles  35 
10 min  72º 
Unlimited  4º 
 
And these amplificats were used for second-round PCR 
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PCR 2 Master Mix 
 
H2O  
 
27.75 μl 
5x Puffer  
 
10 μl 
dNTP (10mM)  
 
1 μl 
Forward-Primer2 (10 pmol/μl) 
  
5 μl 
Reverse-Primer2 (10 pmol/μl)  
 
5 μl 
DNA Polymerase (Go Taq)  
 
0.25 μl 
Total  
 
49 μl 
 
1 μl of the PCR 1 productions were added to PCR 2 Master Mix. 
 
 
Thermal cycling 
 
2 min  94º 
1 min  94º 
1 min  58º 
2 min  72º 
Cycles  35 
20 min  72º 
For ever  4º 
 
PCR products were sequenced on an ABI 3730 XL automated sequencer. Sequences were 
aligned, edited and analyzed with CodonCode Aligner (Dedham, MA, USA) and Se-Al 
(available from http://evolve.zoo.ox.ac.uk). All sequences were submitted to GenBank and 
are available under accession numbers FJ864731- FJ864816. 
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4.4 Purification of restricted DNA by gel extraction 
 
The amplified DNA was separated by electrophoresis on 1.2% agarose gel. The fragments of 
interest were cut from the gel and minimized in size removing extra agarose. Gel slices were 
weighed and 3 volumes of Buffer QG were added to 1 volume of gel.  The slices were 
incubated at 50°C for 10 min and 1 volume of isopropanol was added to the sample and 
mixed. The samples were applied to the QIAquick column, and centrifuged for 1 min. 0.75 ml 
of Buffer PE were added to QIAquick column and centrifuged for 1 min (washing step), then 
the DNA was eluted with 50 μl of water. 
 
 
4.5 PBMCs extraction from peripheral blood 
 
PBMCs were isolated by centrifugation gradient using Biocoll separating solution (10 min at 
2100 rpm) and washed three times for 7 min at 2000 rpm with sterile RPM 1640. The cells 
were than resuspended in complete PBMCs culture media for direct analysis or in the freezing 
medium to be cryporeserved and subsequently used for further investigations.  
 
 
4.6 Flow cytometry  
 
Flow cytometry is a method to differentiate and count cells and microparticles that are tagged 
with fluorescent antibodies. Until a decade ago, the flow cytometer was seen only in research 
laboratories. Recently, it has evolved from its highly specialized research tool status to a 
commonplace clinical assay. The impetus for this change has been that flow cytometry is the 
only technique capable of quantitative measurements of multiple features of individual cells 
in a rapid manner (McCoy and Overton, 1994). Flow cytometry is a generic term, while 
FACS (Fluorescence activated cell sorter) is a trademark of the Becton-Dickinson 
Corporation. 
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4.7 Methodology of flow cytometry 
 
A flow cytometer is made up of three main systems: fluidics, optics, and electronics 
(http://www.bdbiosciences.com) (Fig. 4.1). 
• The fluidics system hydrodynamically focuses the cell stream to the laser beam for 
interrogation. 
• The optics system consists of lasers to illuminate the particles in the sample stream and 
optical filters to direct the resulting light signals to the appropriate detectors. 
• The electronics system converts the detected light signals into electronic signals that can be 
processed by the computer. 
For some instruments equipped with a sorting feature, the electronics system is also capable 
of initiating sorting decisions to charge and deflect particles. Any suspended particle or cell 
from 0.2–150 micrometers in size is suitable for analysis. Cells from solid tissue must be 
disaggregated before analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1: Principle of flow cytometry. 
(http://www.bdbiosciences.com) 
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Light scattering 
A flow cytometer operates by causing a fluid stream to pass single file through a beam of 
light generated by a laser. The photons of light, which are disrupted and scattered and emitted 
by the cells following their interaction with the laser beam, are separated into constituent 
wavelengths by a series of filters and mirrors (McCoy and Overton, 1994). The deflection of 
the beams depends upon impact of the laser beams on the cells and is divided into two 
categories. The light which detects the relative size of the single cells is called forward scatter 
(FSC) light, and the light which is deflected by 90° and thus reveals data about the inner 
granularity of the cells is called sideward scatter (SSC) light (http://www.bdbiosciences.com) 
(Fig. 4.2). 
 
 
 
 
 
 
 
 
 
Fig. 4.2: Preliminary identification of cells based on FSC v/s SSC. 
(http://www.bdbiosciences.com) 
 
 
 
Fluorochromes 
A fluorescent compound (fluorochrome) absorbs light energy over a range of wavelengths 
that is characteristic for that compound. This absorption of light causes an electron in the 
fluorescent compound to be raised to a higher energy level. The excited electron quickly 
decays to its ground state, emitting the excess energy as a photon of light. This transition of 
energy is called fluorescence (http://www.bdbiosciences.com). These methods enable, 
amongst other things, a quantitative investigation of the surface molecules. The basis for this 
is an antigen-antibody reaction conducted with fluorescently-marked antibodies which are 
aimed at particular surface molecules. The single cell suspensions are analyzed by flow 
cytometry (Fig. 4.3). 
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Fig. 4.3: Specific binding of fluorochrome-labeled antibody to cell surface antigens. 
(http://www.bdbiosciences.com) 
 
 
 
Signal detection 
Light signals are generated as particles pass through the laser beam in a fluid stream. These 
light signals are converted to electronic signals (voltages) by photodetectors and then assigned 
a channel number on a data plot. A voltage pulse is created when a particle enters the laser 
beam and starts to scatter light or fluoresce. Once the light signals, or photons, strike one side 
of the PMT or the photodiode, they are converted into a proportional number of electrons that 
are multiplied, creating a greater electrical current. The electrical current travels to the 
amplifier and is converted to a voltage pulse. The highest point of the pulse occurs when the 
particle is in the centre of the beam and the maximum amount of scatter or fluorescence is 
achieved. As the particle leaves the beam, the pulse comes back down to the baseline 
(http://www.bdbiosciences.com) (Fig. 4.4). 
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Fig. 4.4: Formation of a voltage pulse. 
(http://www.bdbiosciences.com) 
 
 
 
 
 
 
 Methods 
 46 
 
4.8 Polyclonal antigen-specific expansion of T cells and FACS analyses 
 
Two overlapping peptide sets (each 85 peptides 15-18 amino acids in length) covering local 
consensus sequences from HCV GT1b and 3a were generated with PeptGen (available at 
http://hcv.lanl.gov/) and synthesized (≥ 70 % purity) together with additional twelve 
previously defined optimal epitopes (Table 3.9). The overlapping peptides were combined in 
9 pools for each GT (9-10 peptides/pool).  Fresh or crypreserved PBMCs (2 x 106) were count 
using the Trypan blue exclusion assay. The reactivity of trypan blue is based on the fact that 
the chromopore is negatively charged and does not interact with the cell unless the membrane 
is damaged. Therefore, all the cells that exclude the dye are viable (Fig 4.5). Aliquot was 
diluted with 0.4 % Trypan blue stain and 10 μl of the diluted aliquot solution is transferred 
onto the Neubauer cell counting chamber and covers lipped to be examined under microscope 
(at 10x) for cell counting. 
 
 
 
 
 
 
 
 
 
Fig. 4.5: Illustration of viable cell counting using Trypan Blue exclusion assay.  
Grid with viable cells appears white and dead cells appear blue from the Trypan Blue dye. 
(http://www.bme.gatech.edu/vcl/Tissue_Engineering/Background/6_cell_passaging.htm) 
 
 
Formula for counting number of viable cells for the total cell concentration: Number of 
cells/ml = number of cells over a large square x dilution factor x 104. Meanwhile, the 
suspensions in the tubes were centrifuged at 1700 rpm at 20°C for 7 min. The cell pellet was 
resuspended in 1 ml of PBMCs culture medium on a 24-well plate and stimulated with 
peptide pools (each peptide 1 μg/ml) or optimal defined peptides (1 μg/ml). On day 3 and 7, 1 
ml of complete medium and recombinant IL-2 (2.5 μl/ml) were added. On day 10, the cells 
were tested for IFNγ secretion after stimulation with the same peptide pool by intracellular 
cytokine staining. For this purpose an aliquot of 100 μl of each cell suspension was incubated 
in the presence or absence of the peptide pool (10 μg/ml) and single optimal peptides (1 
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μg/ml) on a 96-well plate at 37°C. After 60 min 5 μl Brefeldin A were added. After 5 hours 
cells were washed twice in PBS containing 1% FCS and stained with 1 μl CD4-PE, 1 μl CD8-
APC and 4 μl Viaprobe for 30 min at 4°C. Cells were washed once in cold PBS containing 
1% FCS and incubated in Fixation/Permeabilization solution for 20 min at 4°C. Cells were 
then washed three times in BD Perm/Wash buffer before adding 0.25 μl IFNγ-FITC. Cells 
were then analyzed on the FACS Calibur. Pools were considered positive when the frequency 
of CD8+IFNγ+ cells in the presence of peptides was at least three times higher as the 
frequency of CD8+IFNγ+ cells in the absence of peptides. The individual reactive peptide in 
positive pools was identified the next day by re-stimulation with single peptides followed by 
IFNγ staining. Data were acquired from 30,000 to 60,000 lymphocyte-gated events per 
sample. The fluorescently-stained characteristics of the cells were measured on FACS Calibur 
and evaluated either with Cell quest software or FlowJo software. 
 
 
4.9 DNA extraction from PBMCs 
 
HCV-DNA was extracted from patient’s PBMCs by using a QIAamp DNA Blood Mini Kit 
50. As shown in the manufacturer’s instructions, 200 μl of PBMCs suspension (up to 5 x 106 
lymphocytes) were pipetted in a 1.5 ml microcentrifuge tube containing 20 μl of QIAGEN 
Protease.  200 μl of Buffer AL were added to the sample and incubate at 56°C for 10 min. The 
lysate was mixed with 200 μl of EtOH (96–100%) then transferred to the QIAamp Mini 
column and centrifuged for 1 min at 8000 rpm. This mixture was applied to the QIAamp Mini 
spin column (in a 2 ml collection tube), and centrifuged at 8000 rpm for 1 min. The column 
was washed with 500 μl AW1 and 500 μl AW2 buffers. The viral DNA was eluted in 200 μl 
Buffer AE and quantified by spectrophotometry. An aliquot of the DNA was HLA-typed 
using standard molecular techniques, while the rest was kept at -20°C. 
 
 
4.10 Identification of cross-reactive peptides 
 
The prediction of the optimal epitopes from each reactive response previously detected was 
performed utilizing the MHC class I binding predictions tool from the Immune Epitope 
Database and Analysis Resource (http://www.iedb.org/). The degree of cross-GT reactivity 
was determined by cultivating PBMCs in the presence of the GT1b and GT3a sequence of 
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every reactive peptide. The cells were thawed in a water bath of 37°C, transferred into a 
medium containing 1 ml of FBS and 10 ml of RPM 1640 ml and centrifuged for 7 min at 
1700 rpm and 4°C. The pellet was rinsed again to remove the DMSO from the medium 
completely. As previously described (see Methods, paragraph 4.8) after 10 days both cultures 
were re-simulated with the GT1b and the GT3a peptide before intracellular IFNγ-staining. 
Lack of cross-reactivity between genotypes was assumed when no specific T cells were 
expanded in the presence of one peptide in at least two attempts or when the frequency of 
CD8+IFNγ+ T cells upon re-stimulation of the non-reactive peptide was more than 10-fold 
below the frequency of the reactive peptide. Full cross-GT reactivity was assumed when 
specific T cells were expanded in the presence of both peptides and when the frequency of 
CD8+IFNγ+ T cells of one peptide was less than 10-fold reduced and there was a less then 
10-fold difference in the peptide concentration needed to stimulate 50% of the maximum 
response (SD50). Partial cross-GT reactivity was instead assumed when specific T cells were 
expanded in the presence of both peptides and when the frequency of CD8+IFNγ+ T cells in 
the presence of the highest concentration (10 μg/ml) of one peptide was less than 10-fold 
reduced but there was a more then 10-fold difference in the SD50. The results were than 
acquired by FACS Calibur and evaluated with either Cell quest software or FlowJo software. 
 
 
4.11 Statistical analysis 
 
Nonparametric Kruskal-Wallis tests, Fisher’s Exact tests and t tests were performed using 
GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA). 
 
 
4.12 HCV serotyping 
 
The enzyme immunoassay has been performed to distinguish antibodies to serotypes 1-6 of 
HCV in human plasma by using Murex HCV Serotiping kit (Abbott, Murex). As shown in the 
manifacturer’s instructions, the plates made up of 96-well coated with HCV peptides were 
incubated with 10 μl of competing solution containing different peptides mixes specific for 1 
to 6 serotypes. 80 μl of sample’s diluents and 10 μl of sample were added to each well and 
incubated for 30 min at 37°C. After two washing steps 100 μl of conjugate and substrate were 
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added respectively and incubated for 30 min at 37°C. In order to identify the specific serotype 
the stop solution was added to each well and within 15 min, the plate was read at absorbance 
at 450 nm (A450) using 690 nm as the reference wavelength.   
 
 
4.13 MHC class I-Pentamers and MHC class I-Pentamer staining 
 
ProImmune has developed Pro5TM MHC Class I Pentamenrs for detecting and enumerating 
CD8+ single antigen-specific T cells using flow cytometry. Pro5TM MHC class I-Pentamenrs 
bind to T cell receptors of a particular specificity, as determined by the MHC class I allele and 
peptide combination. MHC class I-Pentamers can readily be used to detect and separate 
antigen-specific T cell populations as rare as 0.02 % of lymphocytes. Pro5TM MHC class I-
Pentamers comprise five peptide/MHC class I complexes assembled through a coiled-coil 
domain. Due to their planar configuration, all five peptide/MHC class I complexes in the 
MHC class I-Pentamer are available for binding to complementary TCRs. Each Pro5TM MHC 
class I-Pentamer also comprises a PE fluorescent tag for bright and efficient labelling 
(Fig.4.6). Pentamers bind to T cells that express T cell receptors specific for the cognate 
peptide/MHC class I complex and can therefore be used to track antigen-specific T cells by 
flow cytometry. For our purpose an aliquot of 100 μl of each cell suspension was washed with 
FACS buffer incubated with the HLA-A2 peptide-specific MHC class I-Pentamer PE labeled 
on a 96-well plate at RT for 10 min. Cells were washed twice again in FCS buffer and stained 
with 1μl anti-CD8-APC and 2 μl Viaprobe for 30 min at 4°C. The cells were then acquired 
and analyzed by flow cytometry. 
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Fig. 4.6: Schematic representation of MHC class I-Pentamer components. 
(http://www.proimmune.com/ecommerce/htlm/pentamer_info/wbs%201_size6.jpg) 
 
 
4.14 Phenotypical analysis of antigen-specific T cells 
 
Total PBMCs were thawed (see Methods, paragraph 4.10) and stained with MHC class I-
Pentamer as described in the previous paragraph. The ex vivo CD127 expression on peptide-
specific CD8+ T cells was determined staining total PBMCs with CD127-FITC antibody (30 
min at 4°C). The expression of the pro-apoptotic protein Bim was determined ex vivo and 
after 7 days of peptide-specific stimulation (see Methods, paragraph 4.8) staining peptide-
specific CD8+ T cells with the rat anti-human BimS/EL/L antibody (1h at RT) and with the anti-
Rat IgG2-FITC antibody (30 min at RT). To evaluate the proliferation capacity of peptide-
specific CD8+ T cells the percentage of MHC class I-Pentamer positive cells obtained after 7 
days of peptide-specific stimulation was compared to the percentage of cells detected directly 
ex vivo. 
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4.15 AutoMACS Pro technology for enrichment of monocytes 
 
The AutoMACS Separation system was used for the purification of monocytes from PBMCs 
of healthy HLA-A2 buffy coats recruited from the Transfusion Department, Rhine State 
Hospital Essen, University of Duisburg-Essen. Using the magnetic activated cell sorting 
(MACS) technology, monocytes were labeled with super paramagnetic Micro Beads 
(Miltenyi Biotec) coupled with CD14 and purified by immunomagentic separation on 
autoMACS columns. 
 
 
Principle 
MACS® Technology is based on MACS Micro Beads, MACS Separators, and MACS 
Columns. MACS Micro Beads are super paramagnetic particles of approximately 50 nm in 
diameter. They are composed of a biodegradable matrix, and it is therefore not necessary to 
remove them from cells after the separation process. Usually, MACS Micro Beads do not 
alter structure, function, or activity status of labeled cells and are not known to interfere with 
subsequent experiments. Separation of cells using MACS technology takes place inside the 
columns. When a MACS Column is placed in a MACS Separator, a strong permanent 
magnet, a high-gradient magnetic field is induced on the column matrix, which is enough to 
retain cells labeled with minimal amounts of MACS Micro Beads. Unlabelled cells (negative 
fraction) are eluted out while labeled cells (positive fraction) bound to the column are released 
after removal of the column from the magnet. Thus, with MACS Technology both labeled and 
unlabeled cell fractions can easily be isolated with high purity. The entire procedure of 
positive selection or depletion takes less than 20 min, and cells can immediately be used for 
further experiments (http://www.miltenyibiotec.com) (Fig 4.7).  
Cryopreserved PBMCs isolated from a buffy coat of a healthy HLA-A2 donor were washed 
three times with R1640 and counted in order to have 2x107 cells in 160 μl; these cells were 
then incubated with 40 μl of CD14 Microbeads for 15 min at 4°C. After a washing step the 
cells were resuspended in 500 μl of MACS buffer and the monocytes were separated using the 
autoMACS Pro facilities. The negative and positive fractions harvested and aliquots of both 
samples analyzed by flow cytometry to evaluate the purity of the fractions.  
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Step 1 
 
 
 
 
 
 
Step 2 
 
 
 
 
 
 
Step 3 
 
 
 
  
 
Fig. 4.7: Purification of positive fraction of cells by direct magnetic labeling using autoMACS 
technology. 
(http://www.miltenyibiotec.com) 
 
 
4.16 Monocyte maturation 
 
1.5 cells/ml were cultured in DCs maturation medium for two days in a 6-well plate at 37°C 
in a 5% CO2 incubator. An additional 2000/ml of IL-4 and GM-CSF were added on day 2. To 
induce DCs maturation at day 3 a maturation mixture was added containing LPS 100 ng/ml 
and IFNγ 1000 UI/ml. After 48 hours the cells were harvested, washed once with R1640 and a 
sample of 100 ml was stained with CD80-FITC 30 min 4°C to verify the expression of the co-
stimulatory molecule specifically up-regulated in matured DCs. Flow cytometry acquisition 
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was performed using FACS Calibur and evaluated either with Cell quest software or FlowJo 
software. 
 
 
4.17 Activation of memory T cells and priming of naïve peptide-specific T 
cell lines  
 
Two sets of triplicate round-bottom microtiter 96-well were used to activate memory peptide-
specific CD8+ T cells. In one set of wells we plated 200,000 PBMCs of a healthy HLA-A2 
donor, in the other one we co-cultured (200,000) PBMCs with 20,000 autologous DCs to 
verify the activation capacity of monocyte-derived DCs. Both cultures were incubated with or 
without 1 μg/ml of the HLA-A2 peptide of interest to have a positive and negative control of 
the peptide-specific response.  The cells were cultured in 150 μl of co-culture medium 
containing IL-2 (50 UI/ml), IL-7 (5 ng/ml) and IL-15 (5 ng/ml). At day 4 fresh co-culture 
medium (100 μl) and cytokines (IL-2 50 UI/ml, IL-7 5 ng/ml, IL-15 5 ng/ml) were added to 
both cultures using the same concentrations previously described. The cultures were 
maintained for a total of 10 days adding each two days new IL-2, IL-7 and IL-15 always at 
the same concentrations. After this time period new DCs (20,000 cells) were added only to 
the co-culture following the same procedure previously described. After a total of 20 days of 
culture all cells were harvested and tested by IFNγ to identify the activation of memory 
peptide-specific response. The priming of naïve peptide-specific CD8+ T cells was performed 
culturing PBMCs of a healthy HLA-A2 donor with autologous monocytes-derived DCs as 
previously described. The priming of naïve CD8+ T cell lines was analysed by IFNγ and 
MHC class I-Pentamer staining. All the data were than acquired by FACS Calibur and the 
results evaluated by FlowJo software. 
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5 Results: 
 
5.1 Identification of the sequence differences between HCV GT1 and GT3 
 
IVDUs are the population subgroup at greatest risk of HCV infection in more developed 
countries, with prevalence rates of 45% (Judd et al., 2005) and incidence rates of 25% per 
year (Maher et al., 2006). One characteristic of European IVDUs cohorts is the heterogenic 
GT distribution. In the present study we recruited anti-HCV positive individuals (by CMIA) 
in collaboration with the Department of Addictive Behaviour and Addiction Medicine, Rhine 
State Hospital Essen. In all patients the GT was determined by PCR and sequence analysis. 
After analysis of 211 patients we detected that 32% were infected with GT1 (50 GT1a and 12 
GT1b) and 22% were infected with GT3a. Seven additional patients were infected with GT4 
and one with GT2c. In 41% of the patients no HCV-RNA was detectable indicating that these 
patients spontaneously control viral replication (Fig. 5.1). Being highly susceptible to 
reinfection, this subgroup represents a perfect model for studying the impact that multiple 
exposures to different genotypes may have on the immune system.  
 
 
 
 
 
 
 
 
 
 
Fig. 5.1: GT distribution in IVDUs cohort from Essen. 
 
 
The inherent sequence diversity of HCV possibly represents one of the major obstacles for 
immune control (Simmonds, 2004). Complete genomes from different genotypes differ in 
about 30-35% of the nucleotide sites over the complete genome (Simmonds, 2000). Hence, 
the first purpose of this study was to determine the sequence differences between GT1 and 3 
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which represent the predominant genotypes in IVDUs from Essen. The work was performed 
focusing on the NS3 protein of HCV. NS3 is the protease/helicase protein of the virus and is 
recognised as an important target for CD8+ T cell response during acute and chronic HCV 
infection (Diepolder et al., 1995).  
 
Complete NS3 of a total of 42 HCV GT3a isolates and a total of 44 HCV GT1b isolates was 
amplified and sequenced. A GT1b and a GT3a consensus sequence was constructed based on 
the most frequent amino acid in each position of the protein (Fig. 5.2). In this comparison, 
108 of all 631 (17.1%) residues of NS3 differed between the GT1b and GT3a consensus 
sequence. 
 
 
 
Fig. 5.2: NS3 GT1b consensus sequence aligned to NS3 GT3a consensus sequence. 
 
 
To better figure out how this GT-specific sequences could affect the CD8+ T cell responses 
the amino acids differences were analyzed in the range of 9mers, considering that as the 
optimal length for CD8+ T cell epitopes. Only 22% of all 9mers were identical between both 
consensus sequences, 78% of these 9 amino acid windows harboured at least one amino acid 
difference and 48% at least two amino acids differences (Fig. 5.3), indicating that differences 
in targeted epitopes between HCV GT1b and GT3a may be common. 
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Fig. 5.3: Comparison of a GT1b and a GT3a consensus sequence. 
Comparison of a GT1b (based on 44 isolates) and a GT3a consensus sequence (based on 42 isolates). 
The frequency of 9 amino acid windows with the indicated number of differences is given in percent. 
 
 
An example of the GT-specific sequence variability is shown in figure 5.4. The epitopes here 
shown are two previously described HLA-A2 restricted CD8 epitopes which are frequently 
targeted in patients with acute and chronic HCV-infection. The prototype sequence of the 
epitope is shown on top. GT1a sequences randomly taken from a public database and the 
GT1b and GT3a sequences amplified from our cohort were aligned to the prototype epitope 
sequence to address the polymorphisms in these two regions. Both epitopes were overall 
highly conserved within each subtype indicating that the sequence differences observed are 
GT-specific and not the consequence of escape-mutation. In both cases the GT3a and the 
GT1b sequences differed from the GT1a reference sequence (H77) suggesting that even 
subtype-specific differences are potentially relevant.  
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GT 1a GT 1b GT 3a
C I N G V C W T V C I N G V C W T V C I N G V C W T V
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. V . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . S V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T . G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T . G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . A . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . S I . V . . . . . . . T V G . . M . . .
. V . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T . G . . M . . .
. . . . . . . . . . V . . . . . . . T . G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . A . V . . . . . . . T V G . . M . . .
. . . . . . . . A . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . A . . . . T V G . . M . . .
. . . . . . . . . . V . . A . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . . . . . . . . . T V G . . M . . .
. . . . . . . . . . V . . . . . . . T V G . . M . . .
K L V A L G I N A V K L V A L G I N A V K L V A L G I N A V
. . . . . . V . . . . . S S . . . . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . . . V . . . . . L S . . V . . . . . R G M . L . . .
. . T T . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . R . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . M . . . . . . . S S . . L . . . . . R S M . . . . .
. . T . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . M . V . . . . . S G . . . . . . . . R G M . L . . .
. . . . . . . . . . S . A K . . . . . . . . R G M . L . . .
. . . . . . V . . . . . S S . . L . . . . . R G M . L . . .
. . T . . . V . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . . . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . . . . . . . . . S T . . L . . . . . R G M . L . . .
. . . G M . V . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . . . M . V . . . . . S S . . . . . . . . R G M . L . . .
. . . . . . . . . . . . S S . . . . . . . . R G M . L . . .
. . . . . . . . . . . . S G . . L . . . . . R G M . L . . .
. . . T . . V . . . . . S . . . L . . . . . R G M . L Y . .
. . . . . . . . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . . . . . . . S G . . L . . . . . R G M . L . . .
. . . . M . . . . . . . S G . . L . . . . . R G M . L . . .
. . . . . . . . . . . . S S . . V . . . . . R G M . L . . .
. . . . . . V . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . V . . . . . R G M . L . . .
. . . . . . V . . . . . S N . . L . . . . . R G M . L . . .
. . . . . . . . . . . . S . . . L . . . Q . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
. . T . . . V . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S S . . L . . . . . R G M . L . . .
. . . . . . V . . . . . S G . . L . . . . . R G M . L . . .
GT 1a GT 1b GT 3a
A      B 
 
 
Fig. 5.4: Example of GT-specific sequence variability.  
The reference sequence H77 of two immunodominant HLA-A2 epitopes (A: 1073-1081 and B: 1406-
1423) was aligned to GT1a sequences taken from a public database and to GT1b and 3a sequences 
taken from our IVDUs cohort. Differing amino acids from the reference sequence are highlighted.  
 
 
In this work we focused on the relevance that high sequence variability between GT1 and 
GT3 have in T cell immunology.  
 
 
5.2 Impact of GT-specific sequence differences on the CD8+ T cell 
response 
 
There are substantial sequence differences between GT1 and GT3 even in described CD8 
epitopes. The relevance of these sequence differences on CD8+ T cells is unknown. We 
decided to focus the analysis on a subgroup of 53 patients from our cohort. Patients infected 
with GT1 and GT3 as well as HCV-RNA negative patients were included. Patients infected 
with GT2a were excluded from the analysis. To address this we utilized overlapping peptide 
sets (each 85 peptides 15-18 amino acids in length) covering our local consensus sequences 
from HCV GT1b and 3a generated with PeptGen (available at http://hcv.lanl.gov/) and 
synthesized (≥ 70% purity) together with additional 12 previously defined optimal epitopes 
(see: Materials, Table 3.9). The subgroup of 53 subjects included 14 subjects with 
undetectable viremia, 17 subjects with HCV GT1 infection and 22 subjects with HCV GT3 
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GT1 GT3 HCV-RNA-neg°
N 17 22 14
male/female 12/5 15/7 10/4
age in years, mean (SD) 39.5 (8.3) 38.6 (8.6) 43.9 (6.0) n.s.
median HCV VL in IU/mol (interquartile range) 132.783 (52.739-1.215.000) 262.400 (56.095-1.302.000) - n.s.
GPT  in IU/ml, mean (SD) 129.3 (35.6) 113.5 (21.2) 44.8 (17.9) p < 0.05¹
Serotype² 14 x GT1 15 x GT3 4 x GT1
1 x GT4 2 x GT1 2 x GT3
2 x NT³ 1 x GT2 1 x mixed GT1/GT3
1 x mixed GT1/GT3 7 x NT³
3 x NT³
°Versant Transcription-mediated amplfication-Test negative
¹GT1 vs. HCV-RNA negative and GT3 vs. HCV-RNA negative (Kruskal-Wallis-Test)
²Serotyping was performed with the Murex HCV Serotyping Assay
³NT: not typable
infection (Table 5.1). Although seven of 14 (50%) of the HCV-RNA negative subjects were 
not typeable with a HCV serotyping assay, serotype 1 was detected in four subjects, serotype 
3 in two subjects and a mixed GT1/GT3 serotype in 1 additional subject, indicating 
heterogeneous GT exposure also in this group (Table 5.1). 
 
Table 5.1: Cohort characteristics. 
 
 
 
 
 
 
 
 
 
 
To analyse the immune responses of the cohort PBMCs were isolated from each subject, 
cultured and stimulated with peptide pools (each peptide 1 μg/ml) or optimal defined peptides 
(1 μg/ml). On day 10, the cells were tested for IFNγ secretion after stimulation with the same 
peptide pool by intracellular cytokine staining. An aliquot of each cell suspension was 
incubated in the presence or absence of the peptide pool (10 μg/ml). Pools were considered 
positive when the frequency of CD8+IFNγ+ cells in the presence of peptides was at least 
three times higher as the frequency of CD8+IFNγ+ cells in the absence of peptides. The 
individual reactive peptide in positive pools was identified the next day by restimulation with 
single peptides (10 μg/ml) followed by IFNγ staining. An example is shown in figure 5.5, 
after 10 days of in vitro culture the chronically infected patient C73 was tested positive for 
pool 9 with 9.30% of CD8+ T cells secreting IFNγ upon restimulation. In order to identify the 
single reactive peptide, T cells were restimulated the next day with each single peptide 
included in pool 9. Peptide 82 was identified as the one responsible for the IFNγ production 
with a 14.54% of CD8+ T cells secreting IFNγ. This approach was applied for the screening 
of each response in order to identify all the reactive peptides. Step necessary for the further 
identification of the single optimal epitopes. 
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Fig. 5.5: Example of the approach used for the detection CD8+ T cells responses.  
Antigen-specific T cells were expanded in vitro in the presence of peptide pools for 10 days before 
restimulation with the same peptide pool and staining for IFNγ. The reactive peptide in positive pools 
was determined the next day by restimulation with individual peptides. Here peptide 82 was 
considered as being reactive. 
 
 
After screening with the overlapping peptide sets a total of 27 individual epitopes was 
identified (one additional epitope was only detected with an optimal peptide) corresponding to 
a total of 57 CD8 responses (Table 5.2).  
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ID age gender genotype serotype VL* ALT HLA GT1b cons sequence strength GT3a cons sequence strength prototype sequence strength GT3a sequence strength
21 41 male 1a 1 1,278,890 A1,3 B7,8 ATDALMTGY 3,98 ATDALMTGF -
........F .........
23 45 male 1b 1 59 27 A2,29 B15,44
24 43 male 1a 1 206 337 A1,3 B8,27
30 46 female 1b NT 1,777,000 23 A1,3 B8,35
34 38 male 1a 1 133 A2, B40,51
43 47 female 1a 4 3 69 A1,3 B7,8
46 50 male 1a 1 1,674,380 187 A2,25 B7,39
57 29 male 1a 1 1,580,680 A3,30 B7,13
68 28 female 1a 1 1,064 448 A2,32 B15,44 CVNGVCWTV 8,95 TVGGVMWTV -
.I....... CIG..M...
KLSGLGLNAV 0,68 KLRGMGLNAV -
..VA..V... ..ALG.....
73 43 male 1b NT 2 18 A24,30 B13,55 RLGAVQNEV 8,3 RLGPVQNEI 23,42
........A ...A....A
74 45 male 1b 1 179 A1, 24 B8 ATDALMTGY 5,47 ATDALMTGF -
........F .........
78 29 male 1b 1 83 105 A2,32 B35,41 VTPGERPSGMFDSSVL - VAPGERPSGMFDSVVL 1,29
................ .T...........S..
HPNIEEVAL - HSNIEEVAL 3,8
.S....... .........
KLSGLGLNAV 2,56 KLRGMGLNAV -
.......... ..S.L.....
83 33 female 1b 1 47 46 A2,25 B7,44
84 49 female 1b 1 62 31 A1,2 B40,51 KLSGLGLNAV 12,91 KLRGMGLNAV -
......I... ..S.L.....
85 33 male 1a 1 499 122 A2 B7,15 GPKGPITQMYTNVDQDLV 1,03 GAKHPALQMYTNVDQDLV -
SS...VI........... SS.H.VI...........
KLSGLGLNAV 1.41 KLRGMGLNAV -
......V... ..VAL.V...
86 48 male 1b 1 1,150,150 118 A29,32 B40,55
89 25 male 1a NT 65 22 A3,30 B15,39
11 35 male 3a 3 <615 45 A3,26 B39,40 VDFVPVESM 5,2 LQFIPVETL -
LQ.I...TL .........
ELTPAETSVRLRAYL 0,5 DLQPAETTVRLRAYL -
D.Q....T....... ...............
18 32 male 3a 3 440 48 A3,24 B35
19 52 male 3a 2 779 132 A2 B39,52 CVNGVCWTV 5,62 TVGGVMWTV -
T.G..M... .........
26 34 male 3a NT <615 135 A1,11 B57
28 38 male 3a 3 95 A1,3 B7,44 ATDALMTGY 0,31 ATDALMTGF -
........F .........
32 56 male 3a 3 3,507,000 261 A2 B18
36 51 male 3a 3 1,284,000 44 A3,24 B15,55
39 33 female 3a 3 1 69 A2,11 B15,35
44 43 female 3a 3 1,536,000 80 A2,24 B40,51
59 40 male 3a 3 601 329 A3,24 B7,35
60 53 female 3a NT 85 A3,33 B35,38
63 42 male 3a 1 28 30 A2 B7,40 CVNGVCWTV 11,01 TVGGVMWTV -
T.G..M... .........
KLSGLGLNAV 1,75 KLRGMGLNAV -
..RGM..... ..........
64 32 male 3a 3;1 2,387,000 A3,24 B15,35
65 36 female 3a 3 231 A2,24 B39,40
67 33 female 3a 3 20 A2,68 B38,51 GKSTKVPAAYAAQGYKVL 3,23 GKSTKVPAAYVAQGYNVL -
...........V...N.. ..........A.......
IPFYGKAI 9,64 IPFYGKAI 9,98
V....... V.......
CVNGVCWTV 4,05 TVGGVMWTV -
T.G..M... .........
70 35 male 3a 3 293,7 A2,24 B18,37 FLATCVNGVCWTVYHGA 5,35 FLGTTVGGVMWTVYHGA -
..G.T.G..M....... .................
71 40 male 3a 3 1,320,000 A2,3 B7,15
76 40 female 3a 3 2,009,000 240 A2,31 B39,40 EFWESVFTGLTHIDAHFL 2,88 DFWESVFTGLTHIDAHFL 4,09
D................. ..................
CVNGVCWTV 8,11 TVGGVMWTV -
T.G..M... .........
77 27 female 3a 1 222 A2 B44 CVNGVCWTV 6,83 TVGGVMWTV -
T.G..M... .........
79 28 male 3a NT 341 A2 B8,13
88 25 male 3a 3 93 A2,32 B51,55 CVNGVCWTV 5,18 TVGGVMWTV -
T.G..M...
90 43 male 3a 3 189 A2 B15,40
9 44 male neg 3;1 - 7 A23 B15,40
10 37 male neg 3 - 21 A30,31 B8,35 GKSTKVPAAYAAQGYKVL - GKSTKVPAAYVAQGYNVL 0,45
AATLGFGSFMSRAYGI - AATLGFGSFMSRAYGI 8,42
HPNIEEVAL 0,41 HSNIEEVAL -
12 44 female neg NT - 68 A2,3 B13,15 RLGAVQNEV 31,92 RLGPVQNEI 52,22
VTLTHPITK 11,51 ICLTHPVTK -
13 41 female neg NT - 236 A1,3 B7,13 HLHAPTGSGK 12,68 YLHAPTGSGK -
GFGAYMSKAH - GFGSFMSRAY 20,12
KLSALGLNAVAYYRGLDV - KLRGMGLNAVAYYRGLDV 5,2
14 42 female neg NT - 19 A2,30 B13,44 GVDPNIRTGV 12,38 GIDPNIRTGN 5,66
SWDQMWKCLIRLKPTLH 1,12 SWDETWKCLVRLKPTLH -
RLGAVQNEV 51,85 RLGPVQNEI 38,95
KLSGLGLNAV 0,44 KLRGMGLNAV -
29 47 male neg 1 - 33 A2,11 B27,44 TLGFGAYMSK 3,73 TLGFGSFMSR -
VTLTHPITK 5,43 ICLTHPVTK -
GRGRRGIYRF - GRGRLGTYRY 14,99
CVNGVCWTV 28,87 TVGGVMWTV -
37 38 male neg NT - 19 A33,68 B40,44 HAVGIFRAAV 13,38 HVAGIFRAAV 7,56
40 49 male neg 1 - 30 A2 B27,44 CVNGVCWTV 0,79 TVGGVMWTV -
42 48 male neg 1 - 14 A2 B14,51 GVDPNIRTGV 2,05 GIDPNIRTGN -
IPFYGKAI 11,9 IPFYGKAI 10,83
CVNGVCWTV 14,06 TVGGVMWTV -
58 50 male neg NT - A3,26 B7,38 GKAIPIEVIKGGRHLIF 1,27 GKAIPIALLKGGRHLIF -
VTLTHPITK 2,88 ICLTHPVTK -
61 39 female neg NT - 31 A2,33 B7,14
62 43 male neg NT - A1,2 B40,51 IPFYGKAI 11,95 IPFYGKAI 18,52
CVNGVCWTV 8,24 TVGGVMWTV -
66 57 male neg 3 - 33 A1,3 B8,35 LIRLKPTL 39,51 LVRLKPTL 43,89
ATDALMTGY 29,26 ATDALMTGF -
HSKKKCDEL 62,5 HSKKKCDEI 59,38
HPNIEEVAL 31,47 HSNIEEVAL 11,95
82 35 male neg 1 - 27 A2 B35,39 CVNGVCWTV 2,64 TVGGVMWTV -
KLSGLGLNAV 1,69 KLRGMGLNAV -
      ant HCV-RNA 3.0 assay (bDNA) with a limit of detection of 615IU/ml
RNA
neg
CD8 epitopes detected with overlapping peptides
GT1
GT3
additional optimal
Table 5.2: List of the identified responses. 
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peptide
status RNA neg GT1 GT3
peptide
status RNA neg GT1 GT3
n.s. n.s. n.s. n.s. n.s. n.s.
p<0.01
p<0.01
p<0.01
p<0.01
HCV-specific T cells were substantially more frequent in HCV-RNA negative subjects 
compared to HCV-RNA positive subjects. HCV-specific CD8+ T cells were detected in seven 
of 17 (41.2%) subjects infected with GT1, in nine of 22 (40.9%) subjects infected with GT3 
and 12 of 14 (85.7%) subjects with undetectable viremia. The total strength and number of 
HCV-specific T cell responses identified with overlapping peptides was significantly higher 
in the HCV-RNA negative group when compared to the GT1 or GT3 infected groups 
(p<0.01). What we also observed was the lack of difference between the strength and 
magnitude of the T cell response directed against GT1 or GT3 peptides in HCV-RNA 
negative subjects. In the subjects with GT1 or GT3 infection there was a trend towards 
preferential targeting of the heterologous GT, although this trend was statistically not 
significant (Fig. 5.6). 
 
A                                                                 B 
 
 
 
Fig. 5.6: Strength and magnitude of the CD8 response in each subject of the IVDUs cohort. 
(A) The relative frequency of HCV-specific T cells and (B) the number of CD8 epitopes detected with 
overlapping peptides (GT1, closed symbols; GT3, open symbols) after 10 days of in vitro 
expansion in the presence of peptide pools is shown. Horizontal lines represent the median. P 
values for the comparison between GT1 and GT3 peptides are indicated (Kruskal-Wallas test 
with Dunn's post test). 
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5.3 Analysis of the degree of cross-GT reactivity of CD8+ T cell epitopes 
 
One of the first goals of this work was to identify cross-reactive peptides between GT1 and 
GT3. The idea was to identify interesting targets that could be used in the development of a 
broad protective vaccine. For this purpose all individual responses were confirmed in a 
second series of cultures utilizing cryopreserved PBMCs and fine-mapped if possible based 
on predicted motifs within the reactive peptide matching the subject’s HLA-type. The 
prediction of the optimal epitopes was performed utilizing the MHC class I binding 
predictions tool from the Immune Epitope Database and Analysis Resource 
(http://www.iedb.org/). The degree of cross-GT reactivity was determined by cultivating 
PBMCs in the presence of the GT1b and GT3a sequence of every reactive peptide as 
described in the previous paragraph. After 10 days both cultures were re-simulated with the 
GT1b and the GT3a peptide before intracellular IFNγ-staining. 
 
Lack of cross-reactivity between genotypes was assumed when no specific T cells were 
expanded in the presence of one peptide in at least two attempts or when the frequency of 
CD8+IFNγ+ T cells upon restimulation of the non-reactive peptide was more than 10-fold 
below the frequency of the reactive peptide. Full cross-GT reactivity was assumed when 
specific T cells were expanded in the presence of both peptides and when the frequency of 
CD8+IFNγ+ T cells of one peptide was less than 10-fold reduced and there was a less then 
10-fold difference in the SD50. Partial cross-GT reactivity was instead assumed when specific 
T cells were expanded in the presence of both peptides and when the frequency of 
CD8+IFNγ+ T cells in the presence of the highest concentration (10 μg/ml) of one peptide 
was less than 10-fold reduced but there was a more then 10-fold difference in the SD50.  
 
Among the 28 epitopes that have been identified in our CD8+ T cell response analysis, only 
three showed an identical consensus sequence between the two genotypes (Table 5.3). 
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position restriction GT1b cons sequence GT3a cons sequence times detected reactive sequence
1069-1085 n.d. FLATCVNGVCWTVYHGA FLGTTVGGVMWTVYHGA 1 1b
1073-1081 A2 CVNGVCWTV TVGGVMWTV 12 1b
1092-1109 n.d. GPKGPITQMYTNVDQDLV GAKHPALQMYTNVDQDLV 1 1b
1175-1184 A68 HAVGIFRAAV HVAGIFRAAV 1 1b, 3a
1193-1201 B40 VDFVPVESM LQFIPVETL 1 1b
1227-1236 A3 HLHAPTGSGK YLHAPTGSGK 1 1b
1235-1252 n.d. GKSTKVPAAYAAQGYKVL GKSTKVPAAYVAQGYNVL 1 3a
1235-1252 n.d. GKSTKVPAAYAAQGYKVL GKSTKVPAAYVAQGYNVL 1 1b
1259-1274 n.d. AATLGFGSFMSRAYGI AATLGFGSFMSRAYGI 1 3a
1261-1270 A11 TLGFGAYMSK TLGFGSFMSR 1 1b
1265-1274 n.d. GAYMSKAHGV GSFMSRAYGI 1 3a
1273-1282 A2 GVDPNIRTGV GIDPNIRTGN 3 1b (3a)
1359-1367 B35 HPNIEEVAL HSNIEEVAL 3 1b (3a)
1373-1380 B51 IPFYGKAI IPFYGKAI 3 1b, 3a
1377-1393 n.d. GKAIPIEVIKGGRHLIF GKAIPIALLKGGRHLIF 1 1b
1395-1403 B8 HSKKKCDEL HSKKKCDEI 1 1b, 3a
1406-1415 A2 KLSGLGLNAV KLRGMGLNAV 7 1b
1406-1423 n.d. KLSALGLNAVAYYRGLDV KLRGMGLNAVAYYRGLDV 1 3a
1436-1404 A1 ATDALMTGF ATDALMTGF 4 1b, 3a a
1487-1501 B27 GRGRRGIYRF GRGRLGTYRY 1 3a
1502-1517 n.d. VTPGERPSGMFDSSVL VAPGERPSGMFDSVVL 1 3a
1529-1543 n.d. ELTPAETSVRLRAYL DLQPAETTVRLRAYL 1 1b
1556-1573 n.d. EFWESVFTGLTHIDAHFL DFWESVFTGLTHIDAHFL 1 1b, 3a b
1603-1619 n.d. SWDQMWKCLIRLKPTLH SWDETWKCLVRLKPTLH 1 1b
1611-1618 B8 LIRLKPTL LVRLKPTL 1 1b, 3a
1627-1635 B13 RLGAVQNEV RLGPVQNEI 3 1b, 3a
1635-1643 A3 VTLTHPITK ICLTHPVTK 2 1b
1636-1643 A11 TLTHPITK CLTHPVTK 1 1b
a consensus sequence in both genotypes is not reactive, this epitope was only detected with described optimal peptide (ATDALMTGY)
b the reactive 18mer has one amino acid difference between GT1b and GT3a at the N-terminal position, the peptide was considered
  identical in the analysis
Table 5.3: List of peptides detected in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.1 Fully cross-GT reactive CD8+ T cell responses 
 
Two of the three epitopes that showed an identical consensus sequence between GT1 and 
GT3 induced cross-reactive responses: the optimal peptide targeting the region 1373-1380 
(this epitope has been described as HLA-B51 restricted epitope by Yerly et al., 2008) and the 
peptide sequence targeting the amino acids region 1556-1573  (Fig. 5.7 and 5.8).  
 
Three subjects of the cohort were able to target the amino acids region 1373-1380 (subjects 
42, 62 and 67). The alignment of GT1 and GT3 sequences indicates that this region is highly 
conserved in both genotypes, pointing out a potential attractive target for immune therapies 
(Fig. 5.7A). As expected, all these subjects were HLA-B51-positive. Two of the subjects 
targeting this epitope were HCV-RNA negative (R42 and R62) and the single subject with 
chronic infection (C67) harboured an autologous sequence variant (VPFYGKAI; Table 5.2). 
T cells directed against the sequence variant VPFYGKAI even if successfully expanded after 
in vitro culture showed to be only partially cross-reactive with the prototype-specific response 
indicating that it may represent an escape variant (Fig. 5.7B). 
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Fig. 5.7: CD8 epitope with identical consensus sequence in HCV GT1 and GT3.  
(A) T cells were expanded for 10 days from PBMCs of subject R42, R62 and C67 in the presence of 
an individual peptide that contains the previously described HLA-B51-restricted epitope B51-1373. 
After in vitro expansion cells were restimulated with 10 μg/ml of the peptide B51-1373 before 
intracellular IFNγ staining. On the right side, HCV GT1a sequences taken from the database and local 
sequences from HCV GT1b and GT3a were aligned to the H77 (NC_004102) reference sequence of 
the epitope region. (B) T cells from PBMCs of the chronically infected subject C67 were expanded for 
10 days with the HLA-B51 prototype and with the autologous variant sequence VPFYGKAI. After in 
vitro expansion cells were restimulated with both peptides (10 μg/ml) before intracellular IFNγ 
staining. The number of IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot 
(relative to all CD8+ T cells in percent). 
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The second response mentioned before was not fine mapped and was directed against two 
GT-specific peptides that differed in one amino acid in the first position (D→E). Although the 
exact location of the optimal epitope sequence within the 18mer is unclear we assume that the 
targeted region is probably identical in GT1 and 3 (Table 5.3). The cross-reactivity of the GT-
specific CD8+ T cells targeting the region 1556-1573 was evaluated based on the number of 
IFNγ producing cells detected after restimulation. The strength of the CD8+ T cell responses 
after heterologous restimulation was comparable to the one obtained after autologous 
restimulation indicating a full cross-reactive response (Fig. 5.8).  
 
To address the polymorphism of the GT1 and the GT3 targeted regions the H77 GT1a 
reference was aligned with the GT1a sequences from the public database and the GT1b and 
GT3a sequences of our cohort. The peptide sequence resulted highly conserved between the 
GT1b and 3a suggesting that the targeted region was with high probability included in the 
identical region (Fig. 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.8: CD8 epitope with highly conserved consensus sequence in HCV GT1 and GT3.  
T cells were expanded for 10 days from PBMCs of subject C76 in the presence of the peptide targeting 
the amino acids region 1556-1573. After in vitro expansion cells were restimulated with both GT-
specific peptide variants (10 μg/ml) as indicated before intracellular IFNγ staining. The number of 
IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot (relative to all CD8+ T 
cells in percent). On the right side, HCV GT1a sequences taken from the database and local sequences 
from HCV GT1b and GT3a were aligned to the H77 (NC_004102) reference sequence of the epitope 
region. 
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Of the total of 28 epitopes the remaining 25 harboured at least one amino acid difference 
between the consensus sequences of GT1b and GT3a. Examples of fully cross-GT reactive 
CD8+ T cell response characterized by targeting of a region that differs between GT1 and 
GT3 are shown in figure 5.9. The RNA negative subject R37 had a CD8 response directed 
against the HLA-A68-restricted epitope. The GT1 and GT3 sequence in the HLA-A68-
restricted epitope differed in position 2 and 3 of the epitope (Fig. 5.9A). The RNA negative 
subject R66 instead had two CD8 responses directed against the B8-1611 and the B8-1395-
restricted epitopes that differed respectively in the second and last position of the epitope 
(Fig. 5.9B and C).  
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Fig. 5.9: Examples of three non-identical CD8 epitopes with full cross-GT reactivity.  
T cells were expanded for 10 days from PBMCs of subject (A) R37 in the presence of the individual 
peptide A68-1175 and of subject (B) R66 in the presence of the individual peptides B8-1611 and (C) 
B8-1395. After in vitro expansion cells were restimulated with both GT-specific peptide variants (10 
μg/ml) as indicated before intracellular IFNγ staining. The number of IFNγ+CD8+ T cells is indicated 
in the upper right quadrant of each dot plot (relative to all CD8+ T cells in percent). On the right side, 
HCV GT1a sequences taken from the database and local sequences from HCV GT1b and GT3a were 
aligned to the H77 (NC_004102) reference sequence of the epitope region.  
 
 
In all the three different cases T cells were successfully expanded in the presence of the GT1 
and the GT3 sequence and the two cultures reacted with both peptide variants suggesting full 
cross-GT reactivity. 
 
 
5.3.2 Partial cross-GT reactive CD8+ T cell responses 
 
Examples of CD8 response with partial cross-recognition are shown in figure 5.10 and 5.11. 
As already mentioned CD8+ T cell responses were classified as partial cross-reactive when 
there was more then a 10-fold difference in the SD50. Two RNA negative individuals of our 
cohort showed these characteristic responses: subject R42 and subject R66. T cells from R42 
directed against the epitope A2-1273 were successfully expanded in the presence of the GT1b 
and the GT3a sequence and showed cross-reactivity in the presence of high peptide 
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concentrations (Fig. 5.10A). However, additional peptide titrations revealed preferential 
targeting of the GT1b sequence (Fig. 5.10B).  
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Fig. 5.10: First example of a CD8 epitope with partial cross-GT reactivity.  
(A) T cells were expanded for 10 days from PMBCs in the presence of GT1b and GT3a peptides as 
indicated. After in vitro expansion cells were restimulated with both GT-specific peptide variants (10 
μg/ml) as indicated before intracellular IFNγ staining. On the right side, HCV GT1a sequences taken 
from the database and local sequences from HCV GT1b and GT3a were aligned to the H77 
(NC_004102) reference sequence of the epitope region. The number of IFNγ+CD8+ T cells is 
indicated in the upper right quadrant of each dot plot (relative to all CD8+ T cells in percent). (B) 
Serial peptide dilutions of the GT1b (rhombus) and GT3a (squares) sequence of the A2-1273 peptide 
were tested. 
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Patient R66 had instead a response targeting the B35-1359 restricted epitope that at the 
highest peptide concentrations already showed evidence of a GT1b sequence preferential 
targeting (Fig. 5.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.11: Second example of a CD8 epitope with partial cross-GT reactivity.  
T cells were expanded for 10 days from PMBCs in the presence of GT1b and GT3a peptides as 
indicated. After in vitro expansion cells were restimulated with both GT-specific peptide variants (10 
μg/ml) as indicated before intracellular IFNγ staining. The number of IFNγ+CD8+ T cells is indicated 
in the upper right quadrant of each dot plot (relative to all CD8+ T cells in percent). On the right side, 
HCV GT1a sequences taken from the database and local sequences from HCV GT1b and GT3a were 
aligned to the H77 (NC_004102) reference sequence of the epitope region.  
 
 
5.3.3 Non cross-GT reactive CD8+ T cell responses 
 
A clear example of a CD8 response without cross-GT reactivity could be obtained from 
subjects C63 and C11 chronically infected with GT3 (Fig. 5.12A and B).  
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Fig. 5.12: Examples of CD8 epitopes without cross-GT reactivity. 
T cells were expanded for 10 days from PMBCs of subjects (A) C63 and (B) C11 in the presence of 
GT1b and GT3a peptides as indicated. After in vitro expansion cells were restimulated with both GT-
specific peptide variants (10 μg/ml) as indicated before intracellular IFNγ staining. The number of 
IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot (relative to all CD8+ T 
cells in percent). On the right side, HCV GT1a sequences taken from the database and local sequences 
from HCV GT1b and GT3a were aligned to the H77 (NC_004102) reference sequence of the epitope 
region.  
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In summary, the majority of epitopes (19 of 28; 67.9%) detected in this study did not show 
any cross-GT reactivity between GT1 and GT3. This includes 13 epitopes (46%) that were 
detected in GT1 only and six epitopes (21%) that were detected in GT3 only. Six of the total 
of 28 epitopes (22%) showed cross-GT reactivity. This includes three epitopes, where the 
targeted sequence is identical in GT1 and GT3 and three additional epitopes that targeted both 
GT-specific variants. Two additional epitopes showed partial cross-reactivity between both 
genotypes. One additional epitope ATDALMTGF could not be classified into any of these 
categories because different patterns of cross-reactivity were observed. The consensus 
sequence of this epitope was not reactive in both genotypes and the responses were only 
detected with the optimal ATDALMTGY described epitope, as direct consequence of an 
escape mutation event (Fig. 5.13). 
 
 
 
 
 
 
 
 
Fig. 5.13: Degree of cross-GT reactivity of the identified CD8 epitopes.  
A total of 28 epitopes identified in this study was categorized as indicated in the figure into those 
epitopes reactive in GT1 or GT3 only, epitopes reactive in both genotypes and identical consensus 
sequence of the targeted region, epitopes reactive in both genotypes and different consensus sequence 
and epitopes with partial cross-GT reactivity. One additional epitope was not classified.  
 
 
5.4 Immunological evidence for exposure to different HCV genotypes  
 
The risk profile and heterogeneous GT distribution of IVDUs raises the possibility that 
repetitive exposures to different genotypes may not be uncommon in this cohort. In order to 
address the possible rate of multiple infections we performed serological analyses. We 
assumed that a discrepancy in serotyping and genotyping patterns might be indicative of the 
frequency of re-exposure to different HCV types. HCV serotype determination was performed 
using the Murex HCV serotyping kit, which is based on the detection of antibodies to type 
specific peptides derived from the NS4 proteins of different HCV genotypes. Two GT3-
infected subjects were identified positive for serotype 1 and a discrepancy between serotype 
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and GT was detected in four of 39 subjects with chronic HCV infection. One additional 
subject had a mixed GT1/GT3 serotype, and five subjects were not typable (Table 5.1). 
Overall in most cases, the serotyping data confirmed the previous HCV-type attribution based 
on genotyping results. 
 
On a cellular level exposure to both genotypes can be suspected if CD8 responses directed 
against both genotypes and without cross-reactivity are detected in the same individual or if 
the detected CD8 response is not reactive with the autologous GT. One example for CD8 
responses directed against both genotypes and without cross-reactivity in the same individual 
is shown in figure 5.14. Subject R13 with undetectable HCV-RNA targets three epitopes in 
NS3 including the HLA-A3 restricted epitope A3-1227 and a novel epitope in GT3 spanning 
amino acids 1265-1274. In the presence of the GT1 sequence of the A3-1227 epitope, T cells 
were expanded that did not cross-react with the GT3 sequence of the epitope. In this case 
there is only one amino acid difference between both genotypes (position 1 of the epitope; 
Fig. 5.14A). In contrast, T cells targeting the novel epitope (1265-1274) were only expanded 
in the presence of the GT3 peptide sequence (Fig. 5.14B). After a close look at the epitopes 
already described in literature emerged that this region entirely overlaps with an HLA-A11-
restricted epitope (A11-1265) previously described in GT1. However, this subject is HLA-
A11-negative and five of ten residues differ in the non-reactive GT1 peptide sequence 
supporting that this is truly a novel GT3-specific epitope.  
 
A  
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Fig. 5.14: Firt example of co-existence of two distinct T cell populations targeting different NS3 
regions in both genotypes. 
T cells were expanded for 10 days from PBMCs of subject R13 in the presence of GT1 and GT3 
peptides targeting (A) the A3-1227 epitope and (B) the amino acids region 1265-1274. After in vitro 
expansion, cells were restimulated with the same peptides (10 μg/ml) before intracellular IFNγ 
staining. The number of IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot 
(relative to all CD8+ T cells in percent). On the right side, HCV GT1a sequences taken from the 
database and local sequences from HCV GT1b and GT3a were aligned to the H77 (NC_004102) 
reference sequence of the epitope region. 
 
 
A second example for exclusive GT1- and GT3-specific T cells in the same individual is 
shown in figure 5.15. Subject R29 with undetectable HCV-RNA targets two NS3 epitopes, 
the HLA-B27-restricted epitope B27-1492 and the HLA-A2-restricted epitope A2-1073. 
Although the B27-restricted epitope was previously reported in GT1a, only the GT3a 
sequence was targeted in this subject (Fig. 5.15A). In contrast, T cells targeting the HLA-A2-
restricted epitope were only expanded in the presence of the GT1 peptide sequence (Fig. 
5.15B). 
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Fig. 5.15: Second example of co-existence of two distinct T cell populations targeting different 
regions in both genotypes. 
T cells were expanded for 10 days from PBMCs of subject R29 in the presence of GT1 and GT3 
peptides targeting (A) the B27-1492 and (B) the A2-1073 epitopes. After in vitro expansion, cells 
were restimulated with the same peptides (10 μg/ml) before intracellular IFNγ staining. The number of 
IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot (relative to all CD8+ T 
cells in percent). On the right side, HCV GT1a sequences taken from the database and local sequences 
from HCV GT1b and GT3a were aligned to the H77 (NC_004102) reference sequence of the epitope 
region. 
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Based on this comparison we found two subjects infected with GT1 and immunological 
evidence for exposure to GT3 and eight subjects infected with GT3 and immunological 
evidence for exposure to GT1. Two T cell populations specific for each GT in the same 
individual were detected in additional five subjects with undetectable viremia. 
 
The detailed analysis of the GT-specific responses gave the opportunity to identify one 
epitope that was predominantly recognised in a GT-specific manner. Three subjects of the 
cohort showed responses against amino acids 1627-1635, and all of them displayed two T cell 
populations reactive against one or the other GT. Two of these subjects were HCV-RNA 
negative (Fig. 5.16A and B) instead the third was chronically infected with GT1 with a viral 
load (1.785 IU/ml) (Fig. 5.17). The targeted epitope is a novel HLA-B13-restricted epitope 
with a two amino acids difference between the GT consensus sequences. In the three patients 
was found the co-existence of GT specific cell populations after peptide-specific expansion. 
One T cell population was expanded in the presence of the GT1 sequence of the epitope 
(RLGAVQNEV) and did not target the GT3 sequence (RLGPVQNEI). The other T cell 
population was expanded in the presence of the GT3 sequence and did not target the GT1 
sequence (Fig. 5.16). 
 
 
 
 
 
 
 
 
 
 
Fig. 5.16: Co-existence of two distinct T cell populations targeting the same region in both 
genotypes in two HCV-RNA negative individuals. 
T cells were expanded for 10 days from PBMCs of subjects (A) R12 and (B) R14 in the presence of 
GT1 and GT3 peptides of the epitope B13-1627. After in vitro expansion, cells were restimulated with 
the same peptides (10 μg/ml) before intracellular IFNγ staining. The number of IFNγ+CD8+ T cells is 
indicated in the upper right quadrant of each dot plot (relative to all CD8+ T cells in percent). 
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To support the fact that these amino acids substitutions were GT-specific the sequences 
present in the HCV database were analysed. The data observed that the A to V substitution in 
position four of the GT3a sequence of the epitope is completely absent from all 44 GT1b 
sequences and present in all 42 GT3a sequences (Fig. 5.17A). 
 
The same pattern was observed in the third chronically infected subject indicating that they all 
have been exposed to both genotypes and that two distinct T cell populations have been 
primed. This subject with detectable HCV GT1a viremia harbours a variant (RLGAVQNEA) 
that has been shown to be similarly targeted when compared to the prototype (Fig. 5.17B). 
 
 
 
 
 
Fig. 5.17: Co-existence of two distinct T cell populations targeting the same region in both 
genotypes in a chronically infected individual.  
T cells were expanded for 10 days from PBMCs of subject C73 in the presence of GT1 and GT3 
peptides of the epitope B13-1627. After in vitro expansion, cells were restimulated with both peptides 
and with the autologous detected variant (RLGAVQNEA) (10 μg/ml) before intracellular IFNγ 
staining. The number of IFNγ+CD8+ T cells is indicated in the upper right quadrant of each dot plot 
(relative to all CD8+ T cells in percent). On the left side, HCV GT1a sequences taken from the 
database and local sequences from HCV GT1b and GT3a were aligned to the H77 (NC_004102) 
reference sequence of the epitope region. 
 
 
Summarizing the data obtained within this close analysis of the cross-reactive immune 
responses emerged that we identified five subjects with undetectable viremia with co-
existence of two GT-specific T cell populations. Suggesting that immune control of two 
different genotypes can be obtained in presence of broad reactive responses. 
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5.5 Broad reactive CD8 responses against both genotypes are mainly 
identified in HCV-RNA negative subjects 
 
Subjects with multiple responses against both genotypes were analysed here to identify if 
cross-GT responses provide some degree of protection from chronic HCV infection. These 
analyses showed that in our cohort CD8 responses active against both genotypes were 
predominantly found in HCV-RNA negative subjects. Nine of 14 (64.3%) subjects with 
undetectable viremia harboured T cells active against GT1b and GT3a. This includes T cells 
that were directed against fully cross-reactive epitopes (four subjects) and T cells that were 
GT-specific, but two T cell populations specific for each GT co-existed (five subjects). T cells 
active against both genotypes instead were only detected in six of 39 (15.3%) subjects with 
detectable HCV-RNA (Fig. 5.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.18: CD8 responses active against GT1b and GT3a. 
The frequency of subjects with fully cross-reactive CD8+ T cells (red region) or with co-existence of 
GT-specific CD8+ T cells against GT1b and GT3a (light blue region) is significantly higher in the 
HCV-RNA negative group compared with the HCV-RNA positive group (Fisher's exact test). 
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ID GT Sequence % of Pentamer+CD8+T cells Sequence % of Pentamer+CD8+T cells
CINGVCWTV KLVALGINAV
124 1a  --------- 0.15  --------- 58.33
125 negative N.A.ª 0.21 N.A.ª 0.08
126 1a  --------- 0.02
127 3a TVG--M--- 0.10
ªN.A.: not applicable
5.6 Analysis of the memory phenotype and of the pro-apoptotic state of 
HCV peptide-specific cells 
 
Phenotypic and functional studies of virus-specific T cells have attempted to define the 
determinants of a successful versus an unsuccessful T cell response in viral infections (Lauer 
et al., 2004). It was described that the number and the strength of responses in chronically 
infected subjects were significantly less strong and frequent compared to RNA-negative 
individuals. This phenomenon has also been observed in the IVDUs cohort previously 
analysed (Fig. 5.6). Until now, the identification of consistent features distinguishing between 
T cell responses that result in self limiting versus chronic HCV infection is still not 
completely understood. For this reason we performed here an analysis of the phenotype of 
peptide-specific CD8+ T cells with the aim to discriminate between T cells of individuals that 
cleared the infection from the ones that got into a chronic state. The analysis performed 
focused on the CD8+ T cells of four individuals targeting two HLA-A2 immunodominat 
epitopes: CINGVCWTV (NS3-10739) and KLVALGINAV (NS3-1406) (Table 5.4). The low 
number of responses presented here is a direct consequence of the difficulties that we 
encountered in the detection of sustained peptide-specific responses necessary for detailed 
phenotypical analyses.  
 
Table 5.4: Epitope sequence analysis correlated with the percentages of Pentamer+CD8+ T cells 
detected ex vivo.  
 
 
 
 
 
 
 
 
 
CD127 is a key molecule associated with the maintenance of memory T cell populations 
(Lang et al., 2005). Therefore we decided to analyse the ex vivo expression of CD127 in 
IVDUs individuals with different clinical outcomes to identify the memory phenotype of 
 Results 
 79 
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96,36%
HCV-Chronic GT3 
A: TVGGVMWTV
74,50%
HCV-Chronic GT1 
A: CINGVCWTV
46,67%
peptide-specific CD8+ T cells. PBMCs of each subject were thawed (see Methods, paragraph 
4.10) and analysed directly ex vivo. The cells were stained with MHC class I-Pentamer, with 
the CD8 antibody (see Methods, paragraph 4.13) and with the CD127 antibody. CD8+ T cells 
specific for CINGVCWTV were identified in four subjects and two subjects showed CD8+ T 
cells targeting the KLVALGINAV epitope. 
 
In figure 5.19 are shown CINGVCWTV peptide-specific CD8+ T cells of three individuals 
with different clinical outcomes. One HCV-RNA negative individual (Fig. 5.19A) and two 
chronically infected subjects with GT1 and 3 respectively (Fig. 5.19B and C).  Peptide-
specific CD8+ T cells of the GT1 infected individual (Fig. 5.19B) showed a significant lower 
CD127 expression compared to the peptide-specific cells of the other two individuals. GT1 
and GT3 isolates were amplified and sequenced as previously described (see Methods, 
paragraph 4.3) to correlate the sequence of the circulating antigen to the level of CD127 
expression in peptide-specific CD8+ T cells. Contrary to the autologous sequence detected in 
the GT3a infected individual that had four GT-specific mutations (A: TVGGVMWTV), the 
autologous sequence detected in the GT1 infected patient showed a full match with the 
epitope targeted by the CD8+ T cells (A: CINGVCWTV). This analysis gave us the proof of 
the influence that the continuous triggering of the TCR have on the memory phenotype of 
peptide-specific CD8+ T cells. Lower CD127 expression on epitope-specific CD8+ T cells 
was also observed in other two chronically infected individuals in whom the sequence of the 
infecting virus fully matched the targeted epitope (Fig. 5.19D).  
 
 A                                 B                                           C 
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Fig. 5.19: Representative example of ex vivo CD127 expression in peptide-specific CD8+ T cells.  
The CD127 expression in HCV-specific CD8+ T cells was analysed in (A) an HCV-RNA negative 
individual, (B) a chronically GT1a infected subject and (C) a chronically GT3a infected individual. 
The percentage of epitope-specific CD8+CD127+ T cells is indicated in the upper right quadrant of 
each plot (relative to all CD8+ T cells in percent). (D) Frequency of CD127 expression on peptide-
specific CD8+ T cells. Each dot represents CD127 expression on epitope-specific CD8+ T cells. 
Horizontal lines represent the mean.  
 
 
To address if the differential expression of the CD127 marker could have an impact on the 
proliferation capacity of peptide-specific CD8+ T cells, PBMCs of each individual were put 
in culture with the corresponding reactive peptide for 7 days (see Methods, paragraph 4.8). 
The frequency of peptide-specific CD8+ T cells obtained after in vitro culture was compared 
to the one detected directly ex vivo to estimate the proliferation index. Peptide-specific CD8+ 
T cells continuously triggered by the antigen had a significantly lower proliferation capacity, 
showing an impaired phenotype ex vivo (Fig. 5.20). 
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Fig. 5.20: Proliferation capacity of HCV-specific CD8+ T cells upon 7 days of peptide-specific 
stimulation.  
The proliferation index was calculated by the formula (frequency of HCV-specific CD8+ T cells after 
culture/frequency of HCV-specific CD8+ T cells ex vivo). Horizontal lines represent the mean.  
 
 
A recent study conducted in HBV infection suggested that a higher expression of the pro-
apoptotic protein Bim in virus-specific CD8+ T cells seemed to be associated with chronic 
infection (Lopes et al., 2008). We decided to define if similarly a peripheral deletion of CD8+ 
T cells could be responsible for the paucity of HCV-specific CD8+ T cell responses in 
chronically infected subjects. PBMCs of each individual were thawed and analysed ex vivo or 
after 7 days of in vitro culture (see Methods, paragraph 4.8-4.10). The cells were stained with 
MHC class I-Pentamer and with the BimS/EL/L antibody (see Methods, paragraph 4.13-4.14). 
In each subject we identified a significant increase in the levels of Bim expression after in 
vitro culture even if there was no significant statistical difference between the levels of 
expression comparing RNA negative patients with chronically infected individuals (Fig. 
5.21).   
 
   A                                B  C 
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Fig. 5.21: Mean fluorescence intensity of Bim expression in CINGVCWTV-specific CD8+ T cells 
ex vivo and after 7 days of peptide-specific stimulation.  
We analyzed the level of Bim expression in peptide-specific CD8+ T cells of (A) an HCV-RNA 
negative subject, (B) a chronically GT1a infected individual and (C) a chronically GT3a infected 
subject. The analyses were performed ex vivo (green) and after 7 days of peptide-specific stimulation 
(red). (C and D) Frequency of Bim expression in HCV-specific CD8+ T cells, each dot represent Bim 
expression on epitope-specific CD8+ T cells (D) ex vivo and (E) after 7 days of peptide-specific 
stimulation. Horizontal lines represent the mean. 
 
 
Even if the number of the responses until now detected was not sufficient to make a strong 
conclusion the level of Bim expression did not seem to differ between the groups analyzed 
here.  
 
 
5.7 DC priming of naïve CD8+ T cells and induction of HCV peptide-
specific T cell lines 
 
The last aim of this work was to establish an assay that could potentially help the generation 
of antigen-specific CD8+ T cells to successfully employ in clinical trials. Studies illustrating 
the role of CD8+ T cells in viral clearance of HCV infection support the notion that an 
adoptive immunity holds promise as a treatment (Li et al., 2008). Therefore we aimed to 
establish a technique for the priming of naïve CD8+ T cells against immunodominant HCV 
epitopes. This assay included the maturation of monocytes into DCs and the co-culture of 
these professional APCs with autologous PBMCs. Addition of the peptide to the co-culture 
allowed than the priming of naïve peptide-specific CD8+ T cell lines. At first we decided to 
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activate a HLA-A2 CD8+ T cell memory response against the HLA-A2 FLU-peptide: 
GILGFVFTL to verify the efficiency of the assay. PBMCs were extracted form the buffy coat 
of a healthy HLA-A2 donor and monocytes were separated from a total of 2x107 cells. The 
isolation procedure was performed with the autoMACS Pro facilities using CD14 Microbeads 
(see Methods, paragraph 4.15). After the separation, aliquots of the positive and negative 
fractions were collected and analysed by flow cytometry in order to verify the purity of the 
positive fraction (Fig. 5.22A and B). Monocytes were than counted by Trypan Blue exclusion 
assay (see Methods, paragraph 4.8) and 1.5 cells/ml were put in culture in a 6-well plate for 5 
days. GM-CSF and IL-4 were added at day 0 and day 2 to promote cell proliferation, instead 
IFNγ and LPS were added at day 3 to obtain monocytes-derived DCs (see Methods, 
paragraph 4.16). The maturation of monocytes into DCs was verified checking the up-
regulation of the co-stimulatory molecule CD80 (Fig. 5.22C). 
 
           A                               B                                        C  
 
 
Fig. 5.22: Purification of monocytes from total PBMCs and maturation into DCs. 
(A) Positive fraction: monocytes isolated from total PBMCs using CD14 MicroBeads. (B) Negative 
fraction: monocyte-depleted PBMCs. (C) Maturation of monocytes (red) into DCs (green) was 
checked based on the up-regulation of the co-stimulatory molecule CD80 after in vitro culture with 
IFNγ and LPS. 
 
 
In a 96-well plate, 20.000 DCs were co-cultured with 200.000 PBMCs. The cells were 
obtained from the buffy coat of a healthy HLA-A2 subject which had CD8+T cell responses 
against the FLU-peptide: GILGFVFTL. This experiment was conducted in triplicate in a final 
volume of 250 μl, adding to each well 1 μg/ml of the peptide. We also exogenously added 
cytokines to promote the expansion of CD8+ T cells (IL-2, IL-7 and IL-15) (see Methods, 
paragraph 4.17). To verify the efficacy of mature DCs in activating antigen-specific memory 
CD8+ T cells we established in parallel three cultures using only PBMCs containing non 
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professional antigen presenting cells (the experiment was conducted with the same parameters 
described above). After 20 days of culture the cells were harvested and tested for IFNγ 
production. The analysis of the results showed that the DCs were able to induce a significant 
higher activation of HLA-A2 FLU memory CD8+ T cells compared to the non-professional 
APCs (Fig. 5.23). 
 
A                                     B 
 
 
 
 
 
Fig. 5.23: Activation of FLU-specific memory CD8+ T cells using monocyte-derived DCs and 
PBMCs loaded with the FLU peptide.  
Peptide-loaded DCs and PBMCs were co-cultured with autologous PBMCs and used to activate a 
FLU-specific memory CD8+ T cells response in vitro. (A) After 20 days of in vitro co-culture the cells 
were harvested and analyzed by IFNγ staining. The number of activated IFNγ+CD8+ T cells is 
indicated in the upper right quadrant of each plot (relative to all CD8+ T cells in percent). (B) The 
experiment was performed in triplicate. P value of the comparison between the peptide-specific CD8+ 
T cells activated by peptide loaded DCs (blue) and peptide loaded PBMCs (red) is indicated (Fisher's 
exact test).  
 
 
After the successful activation of a memory HLA-A2 FLU-specific response the next step 
was to prime naïve CD8+ T cells in healthy individuals. For this purpose we used the HLA-
A2 HCV-peptide: CINGVCWTV (region 1073-1081), the epitope mostly recognized during 
the analysis of the immune responses of the IVDUs cohort previously described (Table 5.3). 
Monocytes were matured into DCs, loaded with the HCV-peptide and put in co-culture with 
PBMCs as mentioned before. The activation of the HLA-A2 FLU memory response (peptide: 
GILGFVFTL) was used as control of the assay’s efficacy. After 20 days of co-culture the 
cells were harvested and analysed by MHC class I-Pentamer/HCV and MHC class I-
Pentamer/FLU staining to verify the proliferation of peptide-specific cells (Fig. 5.24A). An 
ICS was also performed to have a look at the functionality of the expanded cells (Fig. 5.24B). 
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Analyses of the results showed the successful priming of functional naïve CD8+ T cells 
against the HLA-A2 HCV-peptide: CINGVCWTV (Fig. 5.24). 
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Fig. 5.24: Priming of HCV-specific naïve CD8+ T cells and activation of FLU-specific memory 
CD8+ T cells using monocyte-derived DCs.  
Peptide-loaded APCs were used to stimulate autologous CD8+ T cells in vitro. After 20 days of 
culture each cell line was analyzed by (A) MHC class I-Pentamer/peptide and (B) intracellular IFNγ 
staining. The number of (A) MHC class I-Pentamer+CD8+ T cells and (B) IFNγ+CD8+ T cells is 
indicated in the upper right quadrant of each plot (relative to all CD8+ T cells in percent). 
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6 Discussion 
 
 
IVDUs are the population subgroup at greatest risk of HCV infection in more developed 
countries, with prevalence rates of 45% or greater (Miller et al., 2002) and incidence rates of 
25% per year or higher being common (Hahn et al., 2002). Most patients are young male 
adults and it is unclear weather their heroin abuse has an impact on the ability to control viral 
or bacterial infections. In the cohort analyzed here the frequency of patients who seemingly 
control HCV replication (41% Anti-HCV positive and RNA negative) is in the normal range, 
suggesting that the immune response is not substantially impaired per se in these patients. Of 
note, the high risk behaviour in this patient group suggests that repetitive exposures to HCV 
are possible. In a recent survey in local drug consumption facilities in Essen (DCF) 63% of 
drug users reported to be HCV positive and 22% reported needle sharing within the previous 
month (Scherbaum et al., 2009). HCV differs from the HBV and many other infectious viral 
agents for the generation of an immune response that does not necessarily induce protective 
immunity (Aitken et al., 2008). Importantly, in 2002 Mehta et al. reported that previously 
infected IVDUs were significantly less likely to be reinfected, even after accounting for risk 
behaviour. Similarly, Grebely et al. reported in 2006 a significantly lower incidence of HCV 
reinfection in IVDUs than in naïve individuals. These findings indicate that some level of 
protective immunity is induced after a previous infection with HCV. The sequence diversity 
of HCV is believed to represent one of the major obstacles to immune control. Of note, the 
protective effect in the studies by Mehta and Grebely were observed in IVDUs cohorts with a 
very homogeneous GT distribution. In North America HCV GT1 by far predominates also in 
the group of IVDUs (Alter et al., 1999). Therefore, immune control may be easier to achieve 
if re-exposure occurs with the same subtype. Clearance after rechallenge with homologous 
strains has also been observed in chimpanzees (Basset et al., 2001) even if Bukh et al., in 
2008 have shown that it doesn’t seem to be always the case.  
 
In the present study we analyzed the impact of GT-specific sequence differences on the CD8+ 
T cell immune responses in a subgroup of IVDUs cohort (53 anti-HCV positive IVDUs). The 
cohort was composed of 17 infected with GT1, 22 infected with GT3 and 14 HCV-RNA 
negative subjects. Of note, we found that the majority of CD8 responses were GT-specific. 
Considering that in our study the majority of T cell responses were directed against one GT 
only and did not cross-react with the other GT, we were able to show that sequence 
differences are relevant in T cell immunology. Over recent years a great effort was made to 
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improve vectors for antigen delivery or define more efficient vaccine strategies. Interestingly, 
in HCV vaccine design only few studies addressed which protein or peptide sequences are 
optimal for immunization (Yerly et al., 2008). This aspect is relevant considering that HCV, 
like most RNA viruses, circulates in vivo as a complex population of different but closely 
related viral variants, commonly referred to as quasispecies (Martell et al., 1992). The 
importance of sequence differences within the host at the level of quasispecies has been 
previously highlighted. The quasispecies serve as a pool from which variants that harbour 
beneficial mutations are selected. Accordingly, rapid selection of immune escape and drug 
resistance mutations has been observed (Cox et al., 2005). Notably, the sequence differences 
between HCV genotypes are not the result of selection within individuals. Confirmation of 
that can be taken looking at the sequences present in the HCV database (http://hcv.lanl.gov/).  
Most differences are specific for the GT and reproducibly observed across all other isolates of 
the same type.  
 
In this cross-sectional study, the importance of pre-existing immunity on control of viral 
replication was not addressed. For this purpose, it would be necessary to perform a 
longitudinal study in which the CD8+ T cell response is analyzed before re-exposure to HCV. 
However, we identified a number of subjects with undetectable viremia and evidence for 
immune control of two different genotypes indicating that in some patients re-infection can be 
controlled even with a different HCV GT. As already reported, spontaneous clearance of 
HCV infection occurs in 20-50% of acutely infected individuals and is associated with a 
broadly specific and vigorous cellular immune response (Takaki et al., 2000). Therefore, the 
high number of HCV-RNA negative patients (41%) in our cohort maybe unexpected, taking 
into account that they are potentially repeatedly exposed.  
 
Cross-reactive CD8+ T cells represent a high precious repertoire for HCV protection against 
heterologous infections. One of the goals in this work was to identify such cross-reactive 
responses. Cross-reactive T cell responses either target an epitope that is conserved across 
genotypes or different GT-specific variants of the epitope that are equally recognized. In this 
study we identified both kinds of CD8+ T cell responses. Notably, of the 28 epitopes 
identified only three conserved identical consensus sequence between the two genotypes. One 
of the conserved epitopes (HLA-B51-restricted epitope IPFYGKAI1373-1380) was targeted by 
three different individuals. The HLA-B51 is not only highly conserved across all genotypes 
but also within different isolates of the same subtype indicating that sequence variation is not 
well tolerated in this region. A pre-existing T cell response against this epitope would likely 
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be beneficial upon infection with both GT1 and 3. In this study 25 of the identified epitopes 
harboured at least one amino acid difference between the consensus sequences of GT1b and 
GT3a. Based on the different degrees of cross-GT reactivity the identified epitopes were 
classified in cross-reactive, partial cross-reactive and non-cross-reactive epitopes. Three CD8 
responses were cross-reactive against GT1 and 3 despite sequence differences in the targeted 
region. We identified three different patients with such a response, all three targeting different 
epitopes. Because these responses were unique it is unclear whether this degree of cross-
reactivity is characteristic for all CD8+ T cell responses against these epitopes or this 
characteristic belongs only to these particular patients. It was previously suggested that 
existence of high-avidity CD8+ T cells that are able to cross-react with different sequence 
variants is associated with control of viremia (Yerly et al., 2008). Although the total number 
of such responses is too small to draw solid conclusions in this study, it is striking that CD8+ 
T cells cross-reactive with both GT-specific variants were only observed in HCV-RNA 
negative subjects. 
 
The remaining 22 epitopes were partially cross-reactive or not cross-reactive. One epitope 
was not classified. Responses against the HLA-A1-restricted epitope were detected only in 
cells expanded with the optimal described epitope ATDALMTGY but not with the consensus 
sequence ATDALMTGF. The Y to F mutation was previously described as an escape 
mutation (Neumann-Haefelin et al., 2008).  
 
One epitope (restricted by HLA-B13) particularly caught our interest for the following reason: 
we identified three subjects with the co-existence of two GT-specific T cell populations 
targeting the same region. One directed against the GT1 variant while a second was directed 
against the GT3 variant. The co-existence of two GT specific CD8+ T cell populations 
suggested that there had been an exposure to both antigens and priming of two distinct T cell 
populations. However, it is unclear whether this is a consequence of a simultaneous exposure 
to either genotypes or of two subsequent distinct infections with different genotypes. 
Although mixed infections with two HCV genotypes have been reported (Bowden et al., 
2005), they are overall rarely detected even in high-risk groups (Viazov et al., 2000) arguing 
against simultaneous exposure to two HCV genotypes as a common event. It is unclear why 
co-existence of two T cell populations was only observed for the B13-epitope in our study. 
Interestingly, HLA-B13 is associated with delayed disease progression in HIV and this was 
mechanistically linked to T cell responses targeting HLA-B13-restricted epitopes in HIV gag 
(Honeyborne et al., 2007). Of note, two of the three subjects here targeting the HLA-B13-
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restricted epitope were HCV-RNA negative instead the third one chronically infected with 
GT1, was identified as a low carrier (1,785 IU/ml). In this case the autologous sequence of the 
infecting virus had a mutation in the last position of the epitope (RLGAVQNEA) (Fig. 
5.17B). The HLA-B13-response described in this study is the first in HCV; however, the 
impact of HLA-B13 on disease outcome is unclear, as the low frequency of this allele in 
many populations may have precluded a solid analysis.  
 
Although the risk profile was not specifically addressed, in the present study the previously 
reported risk behaviour suggests that multiple exposures to HCV may occur. The comparison 
of GT-specific T cell responses in this study allows conclusions about exposure to different 
HCV genotypes. Immunological evidence for exposure to different genotypes was previously 
reported for both CD4+ (Schulze Zur Wiesch et al., 2007) and CD8+ T cells (Sugimoto et al., 
2005). Multiple studies have shown that a subgroup of chronically infected patients - typically 
those infected with genotypes other than GT1 - can display rather broad and vigorous T 
helper cell responses targeting GT1-derived antigens (Kaplan et al., 2005). The role of these 
responses, (Diepolder et al., 2004) and their contribution to viral control remained unclear. 
Our data suggest that it is unlikely that responses targeting non-autologous sequences 
contribute to viral containment as the autologous sequences are frequently not cross-
recognized. According to these previous studies, multiple exposures could take place taking 
note of the discrepancy between T cell responses and the GT-specific sequence of the 
autologous virus in the targeted region (Sugimoto et al., 2005). We similarly detected a 
mismatch between the GT of the autologous virus and the CD8 response in 10 of 39 subjects 
with chronic infection. In two cases this was supported by serotyping results through the 
detection of serotype 1 in GT3 infected subjects. However, a discrepancy between serotype 
and GT was detected in only four of 39 subjects with chronic HCV infection. One additional 
subject had a mixed GT1/GT3 serotype and five subjects were not typeable (Table 5.1). 
Recent studies suggest that the response against the autologous virus may preferentially be 
impaired and responses against a previously resolved heterologous GT persist (Sugimoto et 
al., 2005). In line with this, there was a trend towards a stronger CD8 response against a 
heterologous GT in the present study, although this trend was not statistically significant. 
Importantly, the strength of these putative memory responses in subjects with chronic HCV 
infection did not reach the same magnitude as it has been observed in HCV-RNA negative 
subjects (Fig. 5.6). Of note, we detected only three epitopes where the autologous sequence 
fully matched with the mapped response. In the majority of cases where the CD8 response 
corresponded to the GT of the isolated virus a divergent epitope sequence was encoded by the 
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autologous virus. In the majority of these variants (five of eight; 62.5%) T cell recognition 
was decreased compared to the prototype consistent with previous studies (Neumann-Haefelin 
et al., 2008). 
 
In the present study we also identified five subjects with undetectable viremia and co-
existence of distinct CD8 responses against each GT suggesting immune control of two 
different genotypes. Importantly, T cells active against both genotypes were more frequent in 
subjects with undetectable viremia (64.3% in HCV-RNA negative versus 15.3% in HCV-
RNA positive). Although we certainly underestimate the true number of CD8 responses - as 
any epitope outside NS3 would have been missed - this raises the possibility that broad 
responses directed to different genotypes characterize a subgroup of individuals among 
IVDUs that are seemingly protected from chronic HCV infection. Prospective studies in high 
risk groups will be needed to confirm this observation. 
 
Despite the presence of an activated immune system most subjects show continued viral 
replication. Survival of HCV, despite virus-specific CD8+ CTLs might be explained by 
several mechanisms: impaired priming by DC dysfunction (Sarobe et al., 2003), selection of 
escape mutations (Hiroishi et al., 2002), impaired cellular effector functions (proliferation, 
cytokine secretion, cytolytic activity) (Wedemeyer et al., 2002) or suppression by CD8+Treg 
cells (Boettler et al., 2005). In mouse models T cells activated in the liver are reported to have 
a dysfunctional phenotype. In vitro experiments revealed that naive T cells are activated by 
liver sinusoidal endothelial cells but do not differentiate into effector T cells. These T cells 
show a cytokine profile and a functional phenotype that is compatible with the induction of 
tolerance. Besides sinusoidal endothelial cells, other cell populations of the liver, such as 
DCs, Kupffer cells and perhaps also hepatocytes, may contribute to tolerance induction by 
deletion of T cells through induction of apoptosis (Knolle and Gerken, 2000). Upregulation of 
the pro-apoptotic molecule Bim has been described in virus-specific cells in HBV infection. 
Bim is one of the pro-apoptotic BH3-only group of proteins from the Bcl-2 family that plays a 
central role in the initiation of apoptosis signalling in lymphocytes (Bouillet et al., 1999). Bim 
has been shown in murine models to be required for the shutdown of the CD8+ T cell 
response in the setting of a superantigenic stimulus (Hildeman et al., 2002) or an acute viral 
infection (Pellegrini et al., 2003). Conversely, downregulation of Bim is critical for CD8+ T 
cell memory survival in the absence of antigen (Sabbagh et al., 2006). A comparison of 
chronically HBV-infected patients and patients who spontaneously resolved HBV-infection 
found a higher expression of Bim in the former group.  
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We therefore tried to address the role of Bim in HCV infection and aimed to characterize the 
phenotype of HCV-specific CD8+ T cells in more detail. During our work it became evident 
that the autologous sequence of the circulating virus had a strong influence on the phenotype 
of specific CD8+ T cells. Upon spontaneous clearance of an infection, virus-specific cells 
typically acquire a memory phenotype with upregulation of the memory marker CD127. In 
line with this specific CD8+ T cells from HCV-RNA negative IVDUs showed high CD127 
expression. Interestingly, patients with an autologous sequence - that differed from the 
prototype epitope sequence and that was not recognized by the CD8+ T cells - also showed 
upregulation of CD127. A recent study that systematically evaluated this observation 
demonstrated that by analysis of CD127 we can distinguish two groups: 1.) A functional 
CD8+ memory population that is directed against a sequence which is absent in the patient 
either by antigen escape or by re-infection with a different GT. 2.) A fully exhausted CD8+ T 
cell population that targets the autologous virus although it is dysfunctional and has poor 
effector functions (Bengsch et al., 2010). We expected that the latter group of CD8+ T cells 
would be continuously activated in the liver and potentially also have upregulation of the pro-
apoptotic molecule Bim. This would also explain the difference not only in the quality of 
HCV-specific CD8+ T cells but also in the quantity of CD8+ T cells between patients with 
chronic HCV infection and those who spontaneously resolved infection. Recent studies 
suggest that lack of vigorous CD8 responses in patients with chronic infection is the result of 
secondary rather than primary CD8+ T cell failure. Cox et al. in 2005 reported that CD8+ T 
cells are primed during acute infection in HCV-RNA positive as well as in HCV-RNA 
negative subjects but these responses are not maintained in those who continue to viral 
persistence. Deletion of these virus-specific CD8+ T cells by apoptosis would be an attractive 
explanation for this event, however, we were unable to identify any differences in the 
expression levels of Bim between the different patient groups here even when we controlled 
for the presence of the correct antigen.  
 
The number of CD8 responses that have been analyzed is still rather low. Unfortunately, the 
challenge to find patients with strong CD8+ T cell responses is relatively high, especially in 
chronically infected individuals. HCV-specific CD8+ T cells were detected and analyzed on 
cryo-preserved PBMCs by staining with MHC class I-Pentamers. It will therefore be 
necessary to increase the number of patients for this analysis before coming to any final 
conclusions. Moreover, future studies should also include analyses of other members from the 
Bcl-2 family that could either promote or block cell survival to better define the role that 
deletion of peptide-specific CD8+ T cells has in HCV persistence. 
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 It is estimated that the incidence of complications from chronic hepatitis, namely, liver 
cirrhosis and hepatocellular carcinoma, will increase in the next few decades (Armstrong et 
al., 2000). At present, chronic liver disease associated with HCV is the leading indication for 
liver transplantation (LT) in many Western countries (Willems et al., 2002). Recurrence of 
HCV infection is (almost) universal after orthotropic LT (Böker et al., 1997). Although a 
small proportion of the patients may progress to a ‘‘healthy’’ carrier state with viremia but 
normal aminotransferase concentrations and normal liver and minimal histological changes 
(Gane et al., 1996), progression to histological chronic hepatitis occurs in the majority of 
HCV-positive transplant patients (Feray et al., 1999).  
 
Different studies have demonstrated the safety and relative efficiency of adoptive-transfer of 
specific T cell clones to treat viral infections (Pahl-Seibert et al., 2005). Injections of 
cytomegalovirus CMV and Epstein-Barr virus EBV-specific T cell clones or lines into 
patients who received an allogenic bone marrow transplant have a protective effect against 
CMV and EBV infection (Walter et al., 1995; Rooney et al., 1998). Injections of HIV-
specific CTL clones to HIV patients lead to a temporary decrease of the number of CD4+ T 
cells infected by HIV (Brodie et al., 1999). Therefore adoptive immunotherapy with antigen-
specific CD8+ T cells seemed to represent a promising application against recurrence of HCV 
infection after LT. The ultimate goal of T cell generation for adoptive therapy is to generate T 
cells that exhibit optimal qualities in terms of function, expansion, survival, homing and 
persistence that can help the eradication of virus infection (Sadelain et al., 2003). There are 
different strategies for the generation of epitope-specific CD8+ T cell line. Virtually any cell 
expressing HLA molecules can be used as a potential APC. However, APCs are not equal in 
their ability to stimulate T cells. The professional APCs, which include DCs, macrophages 
and B cells, are better equipped than other cell types to maximize T cell stimulation.  
 
In this study we decided to induce the priming of naïve CD8+ T cells using the 
immunodomint HLA-A2 HCV-peptide: CINGVCWTV, highly recognised in our IVDUs 
cohort. Monocyte-derived DCs from a healthy patient were co-cultured with autologous 
PBMCs. The expansion of specific T cells was obtained after two rounds of stimulation with 
peptide pulsed DCs and exogenous addiction of cytokines (IL-2, IL-7 and IL-15). The 
successful detection of HCV-specific T cells in polyclonal cultures through IFN-γ 
intracellular staining and MHC class I-Pentamer staining represented a positive achievement 
to further apply for the investigation and development of prophylactic and immunotherapeutic 
vaccines. 
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The future experiments will therefore focus on the establishment of long-lasting and 
functional CD8+ T cell lineages targeting multiple immunodominant HCV epitopes. To 
elucidate the role that various HCV peptides have in the induction of T cell responses and to 
identify the epitopes involved in virus control or clearance.  
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7 Summary 
 
 
GT-specific sequence differences are certainly important in the antiviral immune response 
against HCV. The present study for the first time systematically analyzed the degree of cross-
GT reactivity of HCV-specific T cells at the epitope level. To determine the impact that these 
GT-specific mutations have on the CD8+ T cell responses we analyzed a group of IVDUs 
including subjects with undetectable viremia and individuals with HCV GT1 and HCV GT3 
infection. Overlapping peptide sets covering local consensus sequences from HCV GT1b and 
3a were used to analyze the immune responses of each individual. The total strength and 
number of HCV-specific T cell responses detected were higher in the HCV-RNA negative 
group when compared to the GT1 or GT3 infected groups. Interestingly in the chronically 
infected subjects CD8+ T cells preferentially targeted the heterologous GT. These responses 
more possibly are memory CD8+ T cells of a previously resolved heterologous infection.  
 
Cross-reactive CD8+ T cells are a high precious repertoire for HCV protection against 
heterologous infections. In this work we wanted to identify cross-reactive peptides that could 
be useful for the development of a broad-protective vaccine. 22% of the 28 epitopes identified 
was cross-reactive. This includes epitopes where the targeted sequence was identical in GT1 
and GT3 and epitopes that targeted both GT-specific variants. Although the majority of these 
cells showed only limited cross-reactivity, we were able to identify a number of subjects with 
T cells active against both genotypes. Interestingly, T cells active against both genotypes were 
preferentially detected in HCV-RNA negative subjects. This demonstrates that CD8 responses 
targeting different HCV genotypes can be primed in the same individual and that these 
responses are potentially linked to protection from chronic infection. In the face of a 
heterogeneous genotype distribution in many areas of the world, this has important 
implications for vaccine design.  
 
To define the determinants of a successful versus an unsuccessful CD8+ T-cell response in 
HCV infection we decided to perform phenotypic studies on memory HCV-specific CD8+ T 
cells. We evaluated the expression level of the memory marker CD127 and of the pro-
apoptotic protein Bim in individuals with different clinical outcomes to highlight the role that 
peripheral deletion of peptide-specific CD8+ T cells could have on the paucity of CD8+ T cell 
responses in chronically infected subjects. During our work it became evident that the 
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autologous sequence of the circulating virus had a strong influence on the phenotype of 
specific CD8+ T cells. Upon spontaneous clearance of an infection, virus-specific cells 
typically acquire a memory phenotype with upregulation of the memory marker CD127. In 
line with this specific CD8+ T cells from HCV-RNA negative IVDUs showed high CD127 
expression. Interestingly, patients with an autologous sequence - that differed from the 
prototype epitope sequence and that was not recognized by the CD8+ T cells - also showed 
upregulation of CD127. We expected that the latter group of CD8+ T cells would be 
continuously activated in the liver and potentially also have upregulation of the pro-apoptotic 
molecule Bim. This would also explain the difference not only in the quality of HCV-specific 
CD8+ T cells but also in the quantity of CD8+ T cells between patients with chronic HCV 
infection and those who spontaneously resolved the infection. Unfortunately we were unable 
to identify any differences in the expression levels of Bim between the different patients 
groups here analyzed even when we controlled for the presence of the correct antigen. The 
number of CD8 responses that have been analyzed is still rather low. It will therefore be 
necessary to increase the number of patients for this analysis before coming to any final 
conclusions. 
 
The last part of this study was focused on the establishment of an assay for the priming of 
naïve CD8+ T cells with HCV immunodominant epitopes. For this purpose monocytes from 
healthy individuals were matured into DCs and co-cultured with autologous PBMCs in 
presence of the immunodominant HCV-A2-peptide 1073. The successful detection of HCV-
specific T cells in polyclonal cultures was analyzed through IFN-γ staining and MHC class I-
Pentamer staining. CD8+ T cells are thought to be one of the major responsible for clearance 
in HCV infection, therefore the establishment of a peptide-specific functional CD8+ T cell 
line is an interesting tool that could be applied as adoptive immune transfer for example after 
liver transplantation to prevent reinfection of the allograft. 
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9 Appendix 
 
9.1 Abbreviations 
 
Abbreviations Full name 
aa 
 
Amino acid 
 
ALT 
 
Alanine aminotransferase 
 
APC 
 
Allophycocyanin 
 
APC 
 
Antigen presenting cell 
 
°C 
 
Degree Celsius 
 
CARD 
 
Caspase activation and recruitment domain 
 
CD 
 
Cluster of differentiation 
 
CLDN1 
 
Claudin-1 
 
CMIA 
 
Chemiluminescent microparticle immunoassay 
 
CMV 
 
Cytomegalovirus 
 
C-terminal 
 
Carboxy-terminal 
 
CTL 
 
Cytotoxic T cell 
 
DC 
 
Dendritic cell 
 
DCF 
 
Drug consumption facilities 
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DMSO 
 
Dimethyl sulfoxide 
 
DNA 
 
Deoxyribonucleic 
 
DNase 
 
Deoxyribonuclease 
 
dNTPs 
 
Deoxynucleotide triphosphates 
 
dsRNA 
 
Double-stranded RNA 
 
EBV 
 
Epstein-Barr virus 
 
EMCDDA 
 
European Monitoring Centre for Drugs and Drug Addiction 
 
ER 
 
Endoplasmatic reticulum 
 
EtOH 
 
Ethyl alcohol 
 
FACS 
 
Fluorescence Activated Cells Scanner (Flow cytometer) 
 
FCS 
 
Fetal Calf Serum 
 
Fig 
 
Figure 
 
FITC 
 
Fluorescein isothiocyanate 
 
Foxp3 
 
Forkhead box P3 
 
FSC 
 
Forward scatter 
 
g 
 
Gram 
 
GM-CSF 
 
Granulocyte-Macrophage colony-stimulating factor 
 
GPT Glutamic-Pyruvic Tansaminase 
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GT 
 
Genotype 
  
h 
 
Hour 
 
H2O 
 
Water 
 
HAV 
 
Hepatitis A virus 
 
HBV 
 
Hepatitis B virus 
 
HCV 
 
Hepatitis C virus 
 
HCC 
 
Hepatocellular carcinoma 
 
HIV 
 
Human Immunodeficiency Virus 
 
HVR 
 
Hyper variable region 
 
HLA 
 
Human leucocyte antigen 
 
IFN 
 
Type I interferon 
 
IFNAR 
 
Type I interferon receptor 
 
IFN-γ 
 
Interferon-gamma 
 
Ig 
 
Immunoglobulin 
 
IL 
 
Interleukin 
 
IPS-1 
 
Interferon-β promoter stimulator 1 
 
IRES 
 
Internal ribosome entry site 
 
IRF-3 Interferon regulatory factor 3 
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ISG 
 
Interferon-stimulated gene 
 
IU 
 
International unit 
 
IVDUs 
 
Intravenous Drug Users 
 
Kb 
 
Kilo base 
 
kDa 
 
Kilodalton 
 
l 
 
Liter 
 
LCMV 
 
Lymphocytic choriomeningitis virus 
 
LIL 
 
Liver infiltrating lymphocyte 
 
LT 
 
Liver transplantation 
 
M 
 
Molar 
 
MACS 
 
Magnetic activated cell sorting 
 
mg 
 
Milligram 
 
MHC 
 
Major histocompatibility complex 
 
min 
 
Minute 
 
ml 
 
Millilitre 
 
μl 
 
Microlitre 
 
mM 
 
Millimolar 
 
mol  Mole 
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mRNA 
 
messenger RNA 
 
N.A. 
 
Not applicable 
 
NANBH 
 
Non-A, non-B hepatitis 
 
NFκB 
 
Nuclear factor κB 
 
NK 
 
Natural killer cell 
 
NKT 
 
Natural killer T cell 
 
nm 
 
Nanometer 
 
NR 
 
Non-responder 
 
NT 
 
Not typable 
 
N-terminal 
 
Amino-terminal 
 
NTPase 
 
Nucleoside triphosphatase 
 
OAS 
 
2’-5’ oligoadenylate synthetases 
 
OCLN 
 
Occludin 
 
ORF 
 
Open reading frame 
 
OST 
 
Opiate substitution treatment 
 
PBMC 
 
Peripheral blood mononuclear cell 
 
PBS 
 
Phosphate Buffered Saline 
 
PCR Polymerase chain reaction 
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PD-1 
 
Programmed death 1 
 
PD-L1 
 
Programmed death ligand 1 
 
PE 
 
Phycoerythrin 
 
peg-IFN-α 
 
Pegylated interferon alpha 
 
PKR 
 
Protein kinase R 
 
RdRp 
 
RNA-dependent RNA polymerase 
 
RIG-I 
 
Retinoic acid inducible gene-I 
 
RNA 
 
Ribonucleic acid 
 
RNase L 
 
Ribonuclease L 
 
rpm 
 
Revolutions per minute 
 
RPMI-1640 
 
Roswell Park Memorial Institute Medium 1640 
 
RT 
 
Room temperature 
 
RT-PCR 
 
Reverse transcription-polymerase chain reaction 
 
SD 
 
Sensitizing dose 
 
SR-B1 
 
Scavenger receptor class B member 1 
 
SSC 
 
Sideward scatter 
 
STAT 
 
Signal Transducer and Activator of Transcription 
 
STAT-C Specifically targeted antiviral therapy for HCV 
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SVR 
 
Sustained virological response 
 
TAP 
 
Transporter associated with antigen processing 
 
TCR 
 
T cell receptor 
 
TGF-β 
 
Transforming Growth Factor-beta 
 
TIR 
 
Toll/Interleukin-1 receptor domain 
 
TJ 
 
Tight junction 
 
TLR 
 
Toll-Like Receptor 
 
TNF-α 
 
Tumor necrosis factor-alpha 
 
Treg 
 
Regulatory T cells 
 
U 
 
Unit 
 
U 
 
Uracile 
 
UTR 
 
Untranslated region 
 
VL 
 
Viral load 
 
WHO 
 
World Health Organisation 
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